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EDITORIAL 
 
CURE OR CURSE? COMPLIANCE IN DIGITAL HEALTHCARE 
 	Digitization	–	a	term	one	cannot	avoid	nowadays.	Some	even	speak	of	a	digital	revolution	with	reference	to	the	industrial	revolution	more	than	200	years	ago.	And	both	revolutions	are	truly	comparable	in	the	ways	they	disruptively	change	our	working	and	living	conditions	up	to	the	socio-economic	structure.				After	addressing	aspects	of	Legal	Tech	in	our	last	issue,	we	will	focus	on	the	field	of	healthcare	in	this	fall’s	edition	of	CEJ.	It	is	especially	in	the	healthcare	sector	where	digitization	is	to	develop	its	enormous	disruptive	potential.	Not	only	will	there	be	new	techniques	of	diagnosis	and	treatment,	but	also	massive	changes	to	 the	relationships	between	physicians	and	patients,	providers	and	users	of	healthcare	services:	“The	patient	will	see	you	now”	–	the	title	of	Eric	Topols	bestselling	book	is	not	just	a	play	with	words!	Everything	we	thought	we	knew	for	sure	about	the	structures	of	our	healthcare	system	may	be	put	up-side	 down.	 Needless	 to	 say	 that	 data	 generation,	 processing	 and	 usage	 are	gamechangers	 in	 this	 regard.	 Patient	data	 are	 the	 lubricant	 for	a	developing	healthcare	system	and	keep	 it	 running.	However,	 the	question	remains	open	whether	digitization	will	empower	patients	to	emancipate	and	to	meet	physi-cians	at	eye	level	or	whether	it	will	make	them	even	more	dependent	and	vul-nerable.		Digital	 (r)evolution	 is	 progressing	 rapidly	 and	 legislators	 seem	 to	 struggle	keeping	pace.	The	legal	framework	for	the	(digital)	healthcare	sector	is	complex	and	uncertain.	It	often	seems	to	fail	to	take	the	“glocality”	of	digital	health	care	services	into	account.		New	forms	of	healthcare	–	new	legal	questions:	questions	concerning	contract	design,	 liability,	 settlement,	 data	 generation,	 compatibility	with	 professional	regulations	as	well	as	with	national	and	supranational	law.	A	bunch	of	questions	remain	to	be	answered.	CEJ	aims	to	put	these	pieces	together	in	a	couple	of	is-sues	focusing	on	“E-Health	and	Telemedicine”.	This	edition	is	the	first	one	and	has	been	supported	by	Prof.	Dr.	Michael	Lindemann,	who	holds	the	chair	for	Criminal	Law,	Criminal	Procedure	and	Criminology	at	the	University	of	Biele-feld,	Germany.	In	his	research,	Prof.	Lindemann	focusses	(amongst	other)	on	commercial	and	medical	criminal	law	as	well	as	on	the	criminological	aspects	of	white	collar	and	corporate	crimes.	Prof.	Lindemann	is	also	coordinator	of	the	Bielefeld	Center	for	Healthcare	Compliance	(BCHC).		
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The	edition	features	first-rate	articles	by	specialists	in	the	field	of	healthcare	and	data	security.	Apart	from	that	we	will	face	some	classical	compliance	topics	and	last	but	not	least	CEJ	Founder	Michele	DeStefanos	new	book	Legal	Upheaval	will	be	introduced	and	reviewed.		We	hope	you	enjoy	our	fall	edition!	Because	no	matter	whether	you	appreciate	the	recent	developments	or	find	them	even	frightening	–	the	radical	changes	digitization	causes	in	the	health	care	industry	do	affect	each	of	us	and	are	not	to	be	ignored.		With	our	best	regards,		
	 	
Michele	DeStefano,	Hendrik	Schneider	&	Michael	Lindemann	Founder	and	Content	Curators	of	CEJ		
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BLOCKCHAIN IN EU E-HEALTH – BLOCKED BY THE BARRIER 
OF DATA PROTECTION? 
Ulrich M. Gassner 
AUTHOR 
Ulrich M. Gassner is a professor at the Law School of the University of Augsburg, Ger-
many, and the founding director of the Center for E-Health Law. His main research in-
terests include health law, pharmaceutical law, constitutional, and administrative law and 
data protection law. His publication list counts more than hundred books and articles re-
lated to health law. He also is co-editor of several law journals and book series. Further-
more, Ulrich M. Gassner advises private and public clients on a broad range of health law 
matters, with a focus on e-health law and pharmaceutical law. 
 
ABSTRACT 
Compliance with data protection requirements is always a tricky business and even more 
intricate when it comes to cutting-edge technologies such as distributed ledger technology 
(DLT), better known as Block Chain Technology (BCT). These difficulties increase even 
more when the personal data concerned is accorded a special level of protection, as is the 
case with health data. The following article aims to describe and analyze the legal issues 
associated with this scenario. The focus here is on the European Union's (EU) General 
Data Protection Regulation (GDPR) 1, which took effect on May 25, 2018. Furthermore, 
the functionality of BCT and its possible fields of application in healthcare will be outlined. 
			
1  Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection 
of natural persons with regard to the processing of personal data and on the free movement of such data, and 
repealing Directive 95/46/EC (General Data Protection Regulation) (OJ L 119 of 4.5.2016, p. 1). 
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I. HYPE OR HOPE? 
 
Block Chain Technology (BCT) has recently been referred to as “the most disruptive tech 
in decades“.2 Others consider it a fundamental technology that “has the potential to create 
new foundations for our economic and social systems.”3 In that respect, the Gartner Hype 
Cycle, introduced in 1995 by the technology analyst firm Gartner, Inc., proposes useful 
guidance. The hype cycle model traces the evolution of technological innovations in terms 
of expectations or visibility of the value of the technology. It explains the path that tech-
nologies generally take, from their initial introduction into the market until their eventual 
maturation into useful components of broader solutions.4 According to this model, the 
five key phases of a technology’s life cycle are: 
(1) Innovation Trigger: A potential technology breakthrough kicks things off. Early 
proof-of-concept stories and media interest trigger significant publicity. Often 
no usable products exist and commercial viability is unproven. 
(2) Peak of Inflated Expectations: Early publicity produces a number of success sto-
ries – often accompanied by scores of failures. 
(3) Trough of Disillusionment: Interest wanes as experiments and implementations 
fail to deliver. Producers of the technology shake out or fail. Investments con-
tinue only if the surviving providers improve their products to the satisfaction of 
early adopters. 
(4) Slope of Enlightenment: More instances of how the technology can benefit the 
enterprise start to crystallize and become more widely understood. Second- and 
third-generation products appear from technology providers. More enterprises 
fund pilots; conservative companies remain cautious. 
(5) Plateau of Productivity: Mainstream adoption starts to take off. Criteria for as-
sessing provider viability are more clearly defined. The technology's broad mar-
ket applicability and relevance are clearly paying off. 
In a recent study based on data from more than 3,100 CIOs from 98 countries Gartner 
sees BCT as a whole at the Peak of Inflated Expectations phase, whereas blockchain in e-
health is still assigned to the phase of Innovation Trigger,5 as most initiatives are still in 
alpha or beta stage. But without any doubt BCT in e-health will rapidly ascend to the 			
2  Lucas Mearian, What is blockchain? The most disruptive tech in decades, COMPUTERWORLD (May 31, 2018 
1:35 PM PT), https://www.computerworld.com/article/3191077/security/what-is-blockchain-the-most-dis-
ruptive-tech-in-decades.html?page=2 (last visited Aug. 20, 2018, 01:30 PM). 
3  MARCO IANSITI & KARIM R. LAKHANI, THE TRUTH ABOUT BLOCKCHAIN, IN HBR'S 10 MUST READS 
2018: THE DEFINITIVE MANAGEMENT IDEAS OF THE YEAR FROM HARVARD BUSINESS REVIEW 159 (2018). 
4  See for a critical analysis, Martin Steinert & Ozgur Dedehayir, The hype cycle model: A review and future 
directions, 108 TECHNOL. FORECAST. SOC. CHANGE 28 ff. (July 2016). 
5  GARTNER (ED.), BLOCKCHAIN STATUS 2018: MARKET ADOPTION REALITY (2018), quoted by: Christiane 
Pütter, Erwartungen an Blockchain zurückstutzen, CIO (June 22, 2018), https://www.cio.de/a/erwartungen-
an-blockchain-zurueckstutzen,3580750 (last visited Aug. 20, 2018, 01:30 PM). 	
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Peak of Inflated Expectations phase. Consequently, there is some evidence that the excite-
ment around using BCT in healthcare is growing.6 An example of this may be the some-
what evangelical fervor of some over-enthusiastic early adopters especially in the U.S., but 
also in other tech-savvy countries. Others argue that BCT in healthcare is all hype – a 
technological hammer looking for a nail – and that the complexities of health information 
could prevent its practical use.7 However, most people seem to have recognized that, 
when the dust of the hype clears, BCT may have a significant role to play as a main com-
ponent of the digital transformation of the healthcare sector. According to the Gartner 
study, this technology is upwards of only ten years from mainstream adoption. Therefore, 
it comes as no surprise that many advocates are already pointing to BCT’s potential to 
revolutionize healthcare in terms of the secure and efficient sharing of health data, of fos-
tering patient empowerment, etc.8 
Even good old Europe has jumped on the bandwagon. Within the framework of EU’s 
Horizon 2020 research and innovation program, the research project My Health My Data 
(MHMD) has been funded 3,455.190 EUR (ca. 4 mio. USD). It aims to use BCT to enable 
medical data to be stored and transmitted safely and effectively. The MHMD project is 
centered on the connection between organizations and individuals, encouraging hospitals 
to start making anonymized data available for open research, while prompting citizens to 
become the ultimate owners and controllers of their health data. For these purposes, it 
will create a platform relying on BCT.9 
 
			
6  See, e.g., William Gordon, Adam Wright & Adam Landman, Blockchain in Health Care: Decoding the Hype, 
NEJM Catalyst (February 9, 2017), https://catalyst.nejm.org/decoding-blockchain-technology-health/ (last 
visited Sept. 17, 2018, 10:05 AM). 
7  Id. 
8  See, e.g., CHRISTINA CZESCHIK & RATKO STAMBOLIJA, A QUICK GUIDE TO BLOCKCHAIN IN 
HEALTHCARE, 18 et seq. and passim (2nd ed. 2018); PETER B. NICHOL, THE POWER OF BLOCKCHAIN FOR 
HEALTHCARE: HOW BLOCKCHAIN WILL IGNITE THE FUTURE OF HEALTHCARE, 14 et seq. (2017); AXEL 
SCHUMACHER, BLOCKCHAIN & HEALTHCARE STRATEGY GUIDE 2017: REINVENTING HEALTHCARE: TO-
WARDS A GLOBAL, BLOCKCHAIN-BASED PRECISION MEDICINE, 2 et seq. (2017); Devon S. Connor-Green, 
Blockchain in Heathcare Data, 21 INTELL. PROP. & TECH. L. J. 93, at 106-07 (2017); Leslie Mertz, (Block) Chain 
Reaction: A Blockchain Revolution Sweeps into Health Care, Offering the Possibility for a Much-Needed Data 
Solution, 9(3) IEEE PULSe 4 (2018); Juan M. Roman-Belmonte, Hortensia De la Corte-Rodriguez & E. Carlos 
Rodriguez-Merchan, How blockchain technology can change medicine, 130 POSTGRAD MED 420 (2018); Gor-
don, Wright & Landman, supra note 5; David Randall, Pradeep Goel & Ramzi Abujamra, Blockchain Appli-
cations and Use Cases in Health Information Technology, 8 J HEALTH MED INFORMAT 276 (2017); Stanislaw 
P. Stawicki, Michael S. Firstenberg & Thomas J. Papadimos, What's new in academic medicine? Blockchain 
technology in health-care: Bigger, better, fairer, faster, and leaner, 4(1) INT J ACAD MED 1 (2018); Viola Hoff-
mann, Blockchain technology as an opportunity for more transparency and self-determination, GESUND-
HEITSINDUSTRIE BW (January 15, 2018), https://www.gesundheitsindustrie-bw.de/en/article/news/block-
chain-technology-as-an-opportunity-for-more-transparency-and-self-determination/ (last visited Sept. 17, 
2018, 10:40 AM). 
9  My health, my data - A New Paradigm in Healthcare Data Privacy and Security, (last visited Oct. 10, 2018, 10:40 
AM) http://www.myhealthmydata.eu/. 	
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II. HOW DOES BCT WORK? 
 
BCT was the brainchild of the Bitcoin creator(s) acting under the pseudonym Satoshi 
Nakamoto. Bitcoin saw the light of day in a paper of 2008 and was conceptualized as a 
decentralized, cryptographically empowered currency framework for financial interac-
tions without an intermediary. However, while cryptocurrencies are part of the block-
chain phenomena, BCT is not limited to cryptocurrencies. Rather, BCT has the potential 
to restructure economic and social systems and even create new foundations in them. So 
far there have also been use cases for personal identity verification, land-title deeds, intel-
lectual property ownerships, public and financial records, and digital (or “smart”) con-
tracts that automatically execute when certain pre-defined conditions are met. From a 
technological point of view a smart contract means a piece of software that controls 
and/or documents or even effects a legally relevant activity. 
In general, the blockchain may be defined as a public (distributed) ledger which works 
like a log by keeping a growing list of records, called “blocks”, of all transactions in a 
chronological order, secured by an appropriate consensus mechanism and providing a rec-
ord that is, at least in principle,10 immutable. BCT is also often considered as a decentral-
ized database using the peer-to-peer principle. As opposed to a traditional (e.g., relational) 
database, there is no central ownership. Instead, information is managed through the con-
sensus of the network members, who cooperate to decide what gets added to the database. 
In sum, the exceptional characteristics of BCT include immutability, irreversibility, de-
centralization, persistence and anonymity.11  
 
The three main components of BCT are:  
(1) A peer-to-peer computer network, 
(2) a network protocol, and 
(3) a consensus mechanism.12 
Basically, the peer-to-peer network can be public (unpermissioned, open) or private (per-
missioned13, closed). The main differences between these two types are as follows: 			
10  Cf., e.g., Gideon Greenspan, The Blockchain Immutability Myth, MULTICHAIN (May 4, 2017), 
https://www.multichain.com/blog/2017/05/blockchain-immutability-myth/ (last visited Sept. 17, 2018, 10:40 
AM). 
11  Cf., e.g., Dylan Yaga, Peter Mell, Nik Roby & Karen Scarfone, Draft Nistir 8202: Blockchain Technology Over-
view, NIST (January 2018), https://csrc.nist.gov/CSRC/media/Publications/nistir/8202/draft/docu-
ments/nistir8202-draft.pdf (last visited Sept. 17, 2018, 10:40 AM); ARSHDEEP BAHGA & VIJAY MADISETTI, 
BLOCKCHAIN APPLICATIONS. A HANDS-ON APPROACH, 20-23 (2017); Deepak Puthal, Nisha Malik, Saraju 
P. Mohanty, Elias Kougianos, & Gautam Das, Everything you Wanted to Know about the Blockchain, 7(4) 
IEEE CONSUMER ELECTRONICS MAGAZINE 6 (2018). 
12  CZESCHIK & STAMBOLIJA, supra note 8, at 10 et seq. 
13  Furthermore, permissioned blockchains which allow anyone to join a network once identity and role are de-
fined have to be differentiated from private blockchains, which allow only known or internal nodes to partic-
ipate in the network. 	
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(1) Control over the network. Public chains are controlled by the wide community 
of core developers, users, and miners or validators. In turn, private blockchains 
are governed out by a specific group of people or institutions.  
(2) Consensus mechanism (see below).  
(3) Application. While public chains are mostly used for payments (as seen in 
Bitcoin) or as a platform for decentralized applications’ development (as seen in 
Ethereum), almost all private chains are used for solving specific business tasks.14 
Accordingly, most healthcare BCT projects are based on private blockchains.15 
Each computer in a specific network is called a “node”. If everything is running per pro-
tocol, each node should have a copy of the entire ledger, which is sort of a local database. 
This means if one node disconnects or goes down, no data is lost and the ledger’s con-
sistency will be kept.  
The underlying principle of any transaction is that of public/private key encryption in 
order to generate digital signatures. A user has two keys: a public key to encrypt data and 
a private key to decrypt them. Each block contains a cryptographic hash of the previous 
block, a timestamp, and transaction data (generally represented as a merkle tree root 
hash). And unless one of the parties to the transaction decides to link a public key to a 
known identity it is impossible to match transactions to individuals or organizations. Alt-
hough anyone can see all the transactions on the blockchain no personal information is 
linked to them or made public. This allows any party to validate the integrity of the trans-
action ledger without violating the privacy of the parties involved in the transaction. 
All transactions are verified by a consensus mechanism which is a set of rules utilized by 
the network to verify each transaction and confirm the current state of the blockchain. In 
most cases, public chains use Proof-of-Work (PoW) systems, in which so-called “miners” 
solve cryptographic puzzles to “mine” a block in order to add to the blockchain. This pro-
cess requires an immense amount of energy and computational usage. When a miner 
solves the puzzle, they present their block to the network for verification. Verifying 
whether the block belongs to the chain or not is an extremely simple process. In contrast, 
private blockchains mostly use well-known and established consensus algorithms with 
authentified participants such as modified Proof-of-Authority (PoA). In PoA-based net-
works, transactions and blocks are validated by approved accounts, known as validators, 
who replace miners. However, as there is no “perfect” consensus mechanism, the search 
for a truly decentralized consensus mechanism is still going on.16 
In sum, the result of BCT is an expansive and distributed source of truth built not from 
trust, but through cryptographically enforced consensus. As its most important attribute 
can be considered its immutability: once something has been added to the blockchain, it 			
14  See, e.g., Ivan Grekov, Is the Right to Be Forgotten a Real Problem for Blockchain?, LAWLESS.TECH (Apr. 16, 
2018), https://lawless.tech/is-the-right-to-be-forgotten-a-real-problem-for-blockchain/ (last visited Sept. 17, 
2018, 10:20 AM). 
15  CZESCHIK & STAMBOLIJA, supra note 8, at 10. 
16  CZESCHIK & STAMBOLIJA, supra note 8, at 11; see also, e.g., Basic Primer: Blockchain Consensus Protocol, 
Blockgeeks, https://blockgeeks.com/guides/blockchain-consensus/ (last visited Sept. 17, 2018, 10:20 AM). 	
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is permanently stored in a large number of computers.17 
III. HOW CAN BCT BE APPLIED TO HEALTHCARE? 
 
Realized and probable applications of BCT in healthcare can be divided into eight main 
areas, namely electronic health records (EHR) management and interoperability, biomed-
ical research, medication planning and management, revenue cycle management (RCM), 
procurement policies and supply chain management (SCM), internet of medical things 
(IoMT), health professions education, and international medicine and global health. 
 
A. EHR management and interoperability 
 
Most healthcare systems suffer from the siloing of patients’ health data and a lack of in-
teroperability between different domains. Several current health record systems – in the 
U.S., for example, as well as in most European countries with the exception of Estonia18 
– are composed of an enormous number of disconnected databases. Health records are 
usually spread across various institutions, health care providers, and suppliers that often 
use incompatible databases, without full access to a shared patient database. This lack of 
interoperability leads to enormous inefficiencies.19 
BCT would provide the ability to replace these disparate systems with an integrated sys-
tem that, with the use of smart contracts and fully auditable history, enables peer-to-peer 
interoperability among participants (such as physicians, medical institutions, insurance 
companies, and pharmacies) within transactions.20 Using BCT as a data management tool 
would be especially useful for the implementation of so-called integrated healthcare mod-
els, in which the stationary and ambulatory sectors need to exchange information to create 
an efficient and agreeable patient journey.21 Instant access to an agreed set of data about a 
patient would also mean better data for better care in acute, life-threatening situations 			
17  WRIGHT & LANDMAN, supra note 6. 
18  This small EU member state was the first country to implement a blockchain into their electronic healthcare 
record (EHR) system with the collaboration of a local company named Guardtime, using keyless signature 
infrastructure (KSI), Danielle Siarri, The potential of blockchain in HER, Oct. 6, 2017, 
https://www.himss.eu/himss-blog/potential-blockchain-ehr [last visited Oct. 18, 2018, 10:40 AM]; Johnathon 
Marshall, Estonia prescribes blockchain for healthcare data security, PWC (March 16, 2017), 
http://pwc.blogs.com/health_matters/2017/03/estonia-prescribes-blockchain-for-healthcare-data-secu-
rity.html (last visited Sept. 17, 2018, 10:10 AM); see also the official website https://e-estonia.com/blockchain-
healthcare-estonian-experience/. 
19  CZESCHIK & STAMBOLIJA, supra note 8, at 18. 
20  Randall, Goel & Abujamra, supra note 8; Igor Radanović & Robert Likić; Opportunities for Use of Blockchain 
Technology in Medicine, APPL HEALTH ECON HEALTH POLICY (July 18, 2018), doi: 10.1007/s40258-018-0412-
8; Arlindo Flavio da Conceição, Flavio Soares Correa da Silva, Vladimir Rocha, Angela Locoro & João Marcos 
Barguil, Electronic Health Records using Blockchain Technology, CORNELL UNIVERSITY LIBRARY (April 26, 
2018, https://arxiv.org/abs/1804.10078 (last visited Sept. 17, 2018, 10:10 AM). 
21  CZESCHIK & STAMBOLIJA, supra note 8, at 34. 	
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and for better treatment of chronic longer-term conditions (e.g., diabetes22). Patients 
could be treated more quickly and in a more targeted way. As a result, for example, the 
duplication of examinations or treatments would be prevented, ultimately increasing ef-
ficiency.23 Furthermore, sharing the ledger among the participants would bring transpar-
ency to the whole process of treatment, from monitoring drug compliance to facilitating 
cost controls.24 In addition to offering interoperability, blockchain transactions would 
also have the advantage of being cryptographical and irrevocable, thus ensuring privacy 
across parties25 and reducing fraud.26 Moreover, in the BCT environment, the patient (or 
his relatives) would be able to designate by whom the data can be accessed (and at what 
level of access) by the use of keys that only users would be able to dispose of (either private 
or public).  
The key management and the access control could be encoded in a chaincode, thus ensur-
ing patients’ autonomy and self-determination.27 
 
B. Biomedical research 
 
Lack of reproducibility, related to a wide range of scientific misconduct aspects, from er-
rors to frauds, compromises the outcomes of clinical studies and undermines research 
quality. BCT offers the chance to tackle this huge medical challenge for contemporary 
biomedical research. Study data would be time stamped and publicly more transparent 
than now. All plans, consents, protocols, and outcomes could be stored in a blockchain. 
Furthermore, smart contracts could be used to link together several phases of a clinical 
study.28 Additionally, as a more general factor, the application of BCT could bring about 
the access to a large pool of anonymous and encrypted medical data that could be used 
for personalized drug development and epidemiological studies.29 
 
 			
22  Simon Lebech Cichosz, Mads Nibe Stausholm, Thomas Kronborg, Peter Vestergaard & Ole Hejlesen, How to 
Use Blockchain for Diabetes Health Care Data and Access Management: An Operational Concept, J DIABETES 
SCI TECHNOL (July 26, 2018), doi: 10.1177/1932296818790281. 
23  Hoffmann, supra note 8. 
24  Alevtina Dubovitskaya, Zhigang Xu, Samuel Ryu, Michael Schumacher & Fusheng Wang, How Blockchain 
Could Empower eHealth: An Application for Radiation Oncology, in: Data Management and Analytics for 
Medicine and Healthcare 3, 4-5 (Edmon Begoli, Fusheng Wang & Gang Luo eds. 2017). 
25  CZESCHIK & STAMBOLIJA, supra note 8, at 35; Randall, Goel & Abujamra, supra note 8. 
26  Randall, Goel & Abujamra, supra note 8. 
27  CZESCHIK & STAMBOLIJA, supra note 8, at 35-36; Dubovitskaya, Xu, Ryu, Schumacher & Wang, supra note 
24, at 5; Radanović & Likić, supra note 20; Randall, Goel & Abujamra, supra note 8; Hoffmann, supra note 
8. 
28  Mehdi Benchoufi & Philippe Ravaud, Blockchain technology for improving clinical research quality, 18 TRI-
ALS 335 (2017); Dubovitskaya, Xu, Ryu, Schumacher & Wang, supra note 24, at 5; Radanović & Likić, supra 
note 20. 
29  Radanović & Likić, supra note 20. 	
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C. Medication planning and management 
 
Without any doubt, medication reconciliation is one of the most important tasks related 
to quality of care and patient safety. Using appropriate patient safety algorithms via BCT, 
medication errors, contraindications, and medication prescriptions could be reconciled 
near-instantaneously - without the need for time-consuming medication reconciliation 
processes.30 
 
D. Revenue cycle management (RCM) 
 
BCT can help hospitals and health systems to improve the performance of revenue cycle 
management by reducing denials and boosting patient collections because it allows pay-
ers, providers, and financial institutions to share information via private distributed ledg-
ers.31 
 
E. Procurement policies and supply chain management (SCM)  
 
BCT could considerably improve procurement policies since it would ensure that the sup-
ply of goods is transparent, verifiable, and more efficient. Suppliers could be more easily 
controlled and, if necessary, held accountable for the quality of their products. The logis-
tics of pharmaceutical and medical device manufacturers could profit from BCT espe-
cially as there is a high risk of substandard or counterfeited products entering the supply 
chain. By introducing smart contracts, checks and transactions could be carried out auto-
matically. In transactions, in which no conflicts are detected, even payments might be au-
tomatized.32 
 
F. Internet of medical things (IoMT) 
 
IoMT refers to the collection of medical devices and applications that connect to 
healthcare IT systems through online computer networks. Medical devices equipped with 
WiFi, Bluetooth, or other interfaces allow the machine-to-machine communication that 
is the basis of IoMT. The cybersecurity of the connected medical devices and the vulner-
able sensitive data that passes through the IoMT could be ensured by BCT.33 			
30  CZESCHIK & STAMBOLIJA, supra note 8, at 20 et seq.; Stawicki, Firstenberg & Papadimos, supra note 8. 
31  Kelly Gooch, 4 ways to improve RCM with blockchain, Becker’s Hospital CFO Report (March 28, 2018), 
https://www.beckershospitalreview.com/finance/4-ways-to-improve-rcm-with-blockchain.html (last visited 
Sept. 17, 2018, 10:10 AM). 
32  CZESCHIK & STAMBOLIJA, supra note 8, at 23; Stawicki, Firstenberg & Papadimos, supra note 8. 
33  CZESCHIK & STAMBOLIJA, supra note 8, at 23-4; Bernard Marr, Blockchain And The Internet Of Things: 4 
Important Benefits Of Combining These, Forbes (Jan 28, 2018, 12:28 AM), https://www.forbes.com/sites/ber-
nardmarr/2018/01/28/blockchain-and-the-internet-of-things-4-important-benefits-of-combining-these-two-
mega-trends/#50249c9a19e7 (last visited Sept. 17, 2018, 10:10 AM); Matthew Warner, Two Mega Trends Block-
chain Technology to Secure Internet of Medical Things, Chain-Finance (Aug. 15, 2017, 1:35 AM), 	
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G. Health professions education 
 
Novel methods of health professions education have often been criticized for their lack of 
the ability to ascertain the origin, validity, and accountability of the knowledge that is 
created, shared, and acquired. If based on BCT it will potentially allow improved tracking 
of content and the individuals who create it, quantify educational impact on multiple 
generations of learners, and build a relative value of educational interventions.34  
Additionally, records on this digital ledger could continue to grow during the professional 
life of the physician, archiving attended conferences, written articles, and rates of success-
ful treatments.35 
 
H. International medicine and global health 
 
In the area of academic international medicine and global health, blockchain-enabled as-
sessment systems could lead to an alignment of effort allocation between settings (e.g. 
national and international), the immediate provision of much-needed assistance to low-
resource environments, and the reduction of brain-drain that plagues areas in greatest 
need for healthcare delivery. In terms of its potential impact on the current global 
healthcare system, BCT could be one of the key components of ensuring both stability 
and sustainability in the future.36 
IV. BCT VS. DATA PROTECTION? 
 
A. Patient empowerment by BCT and privacy rules? 
 
As of now, health information is widely controlled by insurance companies and funds, 
hospitals, doctors, and other intermediaries who, while claiming trustworthiness, are in a 
position to exploit that trust within essentially asymmetric power structures. BCT could 
reduce the role of these intermediaries, thus shifting the power balance in favor of the 
patients. It is capable of putting patients at the center of their health data and enabling 
data transactions not only to be secure, but also accessible and under the control of the 
individual patient. If implementing BCT can successfully re-distribute the control of 
health data back to individuals this could make individual access rights obsolete.37 
			
http://www.chain-finance.com/2017/08/15/blockchain-technology-to-secure-internet-of-medical-things/ 
(last visited Sept. 17, 2018, 10:10 AM). 
34  Eric Funk, Jeff Riddell, Felix Ankel & Daniel Cabrera, Blockchain Technology: A Data Framework to Improve 
Validity, Trust, and Accountability of Information Exchange in Health Professions Education, Acad Med. 
(June 12, 2018), doi: 10.1097/ACM.0000000000002326; Radanović & Likić, supra note 20. 
35  Radanović & Likić, supra note 20. 
36  Stawicki, Firstenberg & Papadimos, supra note 8. 
37  Cf. Connor-Green, supra note 8, at 99, 106-07, referring to the U.S. legal situation. 	
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However, BCT cannot solve all trust and privacy concerns surrounding health data pro-
tection. Therefore, it has been proposed that the U.S. federal regulation governing 
healthcare data privacy, the Health Insurance Portability and Accountability Act of 1996 
(HIPAA),38 should be supplemented with stricter rules in line with the model of the 
GDPR39. Coupled with BCT, it would affirm a paradigm shift in the US-American legal 
landscape in terms of data ownership.40 The GDPR, however, does not explicitly refer to 
the intrinsically problematic concept of personal data ownership. Rather, it follows 
merely from the wording of sentence 2 of its Recital41 7, ”Natural persons should have 
control of their own personal data”, that data subjects should be in control of their per-
sonal data. 
The regulation paints the term “personal data” with a very broad stroke. It is defined in 
Article 4(1) GDPR as “any information relating to an identified or identifiable natural 
person (‘data subject’); an identifiable natural person is one who can be identified, directly 
or indirectly, in particular by reference to an identifier such as a name, an identification 
number, location data, an online identifier, or to one or more factors specific to the phys-
ical, physiological, genetic, mental, economic, cultural, or social identity of that natural 
person”. It is well established that personal data that has been encrypted or hashed still 
qualifies as personal data within this definition as it is merely pseudonymized and not 
irreversibly anonymized.42 It follows that not only personal data but also public keys used 
in BCT qualify as personal data, just like data relating to a natural person that is hashed 
to the chain.43 As a consequence, cryptographically modified health data stored, e.g., on a 
distributed ledger of an integrated EHR, in addition to public keys, are subject to the 
GDPR. 
Furthermore, as opposed to the narrower approach of the HIPAA Privacy Rule44 all in-
dividuals, organizations, and companies that are either “controllers”45 or “processors”46 			
38  HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996, Pub. L. No. 104-191, 110 Stat. 1936 
(1996). 
39  Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection 
of natural persons with regard to the processing of personal data and on the free movement of such data, and 
repealing Directive 95/46/EC (General Data Protection Regulation) (OJ L 119 of 4.5.2016, p. 1). 
40  Connor-Green, supra note 8, at 99. 
41  Recitals are important because they are used by the Court of Justice of the European Union (CJEU) and other 
EU institutions in order to interpret any Directive or Regulation. 
42  MICHÈLE FINCK, BLOCKCHAINS AND DATA PROTECTION IN THE EUROPEAN UNION 10-11, SSRN (2017), 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3080322 (last visited Sept. 17, 2018, 4:20 PM); cf. fur-
ther Article 29 Working Party, Opinion 04/2014 on Anonymisation Techniques, 0829/14/EN, 20; but see 
BLOCKCHAIN BUNDESVERBAND, BLOCKCHAIN, DATA PROTECTION, AND THE GDPR 4 (2018). 
43  FINCK, supra note 42, at 12-14. 
44  See, e.g., Connor-Green, supra note 8, at 104-05. 
45  A “data controller” is a party that determines the purposes and means of the processing of personal data, see 
Article 4(7) of the GDPR. 
46  A “data processor” is a party that processes personal data on behalf of the controller, see Article 4(8) of the 
GDPR. 	
		 COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
ULRICH M. GASSNER   |   BLOCKCHAIN IN EU E-HEALTH – BLOCKED BY THE BARRIER OF DATA PROTECTION? 
 
PAGE  14 
of personal data are covered by the GDPR. This does not mean that the regulation applies 
to all processing of personal data of EU citizens or residents, as often incorrectly stated. 
Rather, pursuant to Recital 80 of the GDPR, its territorial scope includes the processing 
of personal data of someone “in the Union” by data controllers or processors outside, 
“where the processing activities are related to the offering of goods or services” to that 
person, even if they do not require payment. According to Recital 23 of the GDPR, the 
appropriate test is based on whether the organization “envisages” offering goods and ser-
vices, not on whether it does in fact offer, supply, or simply obtain personal data.47 
The goal of effective control by data subjects is accomplished by, inter alia, requiring ex-
plicit and informed consent for the collection and use of data (Articles 6(1)(1)(a) and 7 
GDPR) and imposing stiff fines on data controllers or processors for non-compliance 
(Article 83 of the GDPR). One of the cores of the regulation is formed by eight funda-
mental and dispositive rights of the data subjects that are outlined below.  
(1) The right to be informed (Articles 13 and14 of the GDPR): A data subject has the 
right to know how his or her data will be collected, processed, and stored, and for 
what purposes. 
(2) The right to access information (Article 15 of the GDPR): A data subject has the 
right to know how his or her data has been collected, processed, and stored, what 
data exists, and for what purposes. 
(3) The right to rectification (Article 16 of the GDPR): A data subject has the right 
to have inaccurate or incomplete data corrected.  
(4) The right to erasure (“the right to be forgotten”) (Articles 17 and 19 of the 
GDPR): A data subject has the right to have personal data permanently deleted 
without the need for a specific reason as to why he or she wishes to discontinue 
the data storage.  
(5) The right to restriction of processing (Article 18 of the GDPR): A data subject 
has the right to block or suppress his or her personal data being processed or used. 
(6) The right to data portability (Article 20 of the GDPR): A data subject has the 
right to transfer personal data from one data controller to another in a safe and 
secure way and in a commonly used and machine-readable format. 
(7) The right to object to processing of personal data (Article 21 of the GDPR): A 
data subject has the right to object to being subject to public authorities or com-
panies processing their data without explicit consent and to stop his or her per-
sonal data from being included in direct marketing databases. 
(8) The right to not be subject to automated decision-making (Article 22 of the 
GDPR): A data subject has the right to demand human intervention, rather than 
having important decisions made solely by algorithm. 
So, at first sight, there may be a case for supplementing the HIPAA by selected features 			
47  See, e.g., Pascal Schumacher, Territorial cope of application of the GDPR – Change from the principle of terri-
toriality to effects doctrine, in New European General Data Protection Regulation. A Practitioner’s Guide 38-
39 (Daniel Rücker & Tobias Kugler eds., 2018); PAUL VOIGT & AXEL VON DEM BUSSCHE, THE EU GENERAL 
DATA PROTECTION REGULATION (GDPR), 26-29 (2017). 	
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of the GDPR in order to improve health data privacy. But when looking at some of the 
data subject’s rights mentioned above, the question may arise whether a decision has to 
be made between using BCT and applying GDPR-standards. For example, the right of 
erasure appears to be particularly at odds with the immutable nature that is at the core of 
BCT.48 Consequently, the issue whether BCT and GDPR can co-exist, is to be examined 
in more detail below. 
 
B. Does the GDPR block BCT? 
 
1. Systemic tension 
 
Arguably, BCT and the GDPR are profoundly incompatible even at a conceptual level as 
the data protection mechanisms developed for centralized data silos cannot be easily rec-
onciled with a decentralized method of data storage and protection. However, personal 
data in a blockchain system that is encrypted or hashed is still subject to the GDPR and 
public keys used in BCT surroundings are qualified as personal data under EU law.49 
Herefrom results not only a risk that the GDPR renders the operation of blockchains 
unlawful. Rather, this tension reveals also a clash between the goals of the protection of 
privacy on the one hand, and the promotion of innovative technology on the other 
hand.50 However, due to the different construction of unpermissioned and permissioned 
blockchains, the latter being dominant in healthcare, it is obvious that the latter cause 
minor difficulties from the point of view of data protection. In addition, technical solu-
tions that can contribute to BCT's data protection compliance are feasible or have already 
been implemented. This is often overlooked in the sometimes quite simplistic public dis-
cussion.51 We will turn to these issues below. 
 
2. Personal data 
 
While BCT allows for personal data to be stored in the same way as in a database, personal 
can also be stored "off chain" in a separate database and only linked to the blockchain via 
private and public cryptographic keys. Consequently, GDPR compliance can be ensured 
			
48  See, e.g., Samuel Martinet, GDPR and Blockchain: Is the New EU Data Protection Regulation a Threat or an 
Incentive?, Cointelegraph (May 27, 2018), https://cointelegraph.com/news/gdpr-and-blockchain-is-the-new-
eu-data-protection-regulation-a-threat-or-an-incentive (last visited Sept. 17, 2018, 10:10 AM). 
49  See supra section IV. 
50  Cf. FINCK, supra note 42, at 1-2, 28-29; cf. also Anne Toth, Will GDPR block Blockchain?, World Economic 
Forum (May 24, 2018), https://www.weforum.org/agenda/2018/05/will-gdpr-block-blockchain/ (last visited 
Sept. 17, 2018, 10:10 AM). 
51  See, e.g., Gyula Pal, The GDPR blockchain blind-spot: Regulating data and everything else, IBM (Jun 26, 2018), 
https://www.ibm.com/blogs/blockchain/2018/06/the-gdpr-blockchain-blind-spot-regulating-data-and-eve-
rything-else/ (last visited Sept. 18, 2018, 01:15 AM); Toth, supra note 50 	
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in that respect.52 This would be the case, for example, if the EHR themselves continue to 
be stored in hospital databases, i.e., off the chain. However, such a workaround has the 
disadvantage that the benefits of transparency and data control with BCT are reduced. 
Thus, paradoxically, in this context the application of the GDPR leads to a result that is 
at odds is with its explicit goal that “natural persons should have control of their own 
personal data” (Recital 7).53 
Unlike transactional data, public keys cannot be moved off-chain as they are quintessen-
tial components of the BCT. Different promising work-arounds have been developed re-
cently, but it is difficult to say at this stage whether any of these techniques will be con-
sidered capable of anonymizing public keys for GDPR purposes.54 
 
3. Legal status of participants 
 
As the GDPR was designed in a pre-BCT-world with a clear division of responsibilities 
between controllers and processors, the legal status of the different participants in block-
chain networks is rather ambiguous. Especially public blockchains do not fit cleanly in 
this model. Namely, nodes cannot be considered data controllers in such a setting as they 
do not determine the means and purposes of the processing of personal data sent to the 
network by a third party.55 When it comes to private blockchains, however, it might still 
be possible to identify a central intermediary. A governance body may be established to 
oversee the permissioned network. This governance body could not only function as a 
data processor if it has influence over the purpose and means of processing within the 
meaning of Article 4(7) of the GDPR but also as a data controller who collects personal 
data from individuals serving as a single point of legal contact with the network.56 
 
 
4. Data minimization 
 
An important principle in the GDPR is data minimization. Article 5(1)(c) of the GDPR 
requires that personal data shall be “adequate, relevant and limited to what is necessary in 
relation to the purposes for which they are processed”. This principle is profoundly at 			
52  Cf. FINCK, supra note 42, at 11-12; BLOCKCHAIN BUNDESVERBAND, supra note 42, at 4; Andries Van Hum-
beeck, The Blockchain-GDPR Paradox, TheLedger (Nov. 21, 2017), https://me-
dium.com/wearetheledger/the-blockchain-gdpr-paradox-fc51e663d047 (last visited Sept. 18, 2018, 01:15 AM); 
Lucas Mearian, Will blockchain run afoul of GDPR? (Yes and no), Computerworld (May 7, 2018 3:02 AM 
PT), https://www.computerworld.com/article/3269750/blockchain/will-blockchain-run-afoul-of-gdpr-yes-
and-no.html (last visited Sept. 17, 2018, 10:15 AM); Luke Sayer, Comment: Can GDPR and blockchain co-exist?, 
International Investment (May 4, 2018), http://www.internationalinvestment.net/comment/comment-can-
gdpr-and-blockchain-co-exist/ (last visited Sept. 18, 2018, 01:15 AM). 
53  Cf. Van Humbeeck, supra note 52. 
54  FINCK, supra note 42, at 14-16. 
55  FINCK, supra note 42, at 16-17; BLOCKCHAIN BUNDESVERBAND, supra note 42, at 5-6. 
56  FINCK, supra note 42, at 16; BLOCKCHAIN BUNDESVERBAND, supra note 42, at 7. 	
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odds with data storage in a blockchain since distributed ledgers are by definition ever-
growing creatures accumulating further data with each additional block.57 
 
5. The right to rectification 
 
Data subjects’ rights under Article 16 of the GDPR imply that a rectification request can 
be addressed to any or all nodes. Two technical hurdles arise in this context. First, even in 
a permissioned blockchain – standard in healthcare environments – the data subject will 
face difficulties to identify any or all of the owners of the nodes. Second, even if the data 
subject succeeds in submitting a claim under Article 16 GDPR, they are simply unable to 
change any of the encrypted data stored in blocks due to their immutable nature. Again, 
an off-chain solution may operate as a legal loophole in that respect.58 
 
6. The right to access information 
 
With respect to Article 15 of the GDPR similar practical difficulties arise. Controllers do 
not know what personal data is stored on the blockchains, since they normally handle 
only the encrypted or hashed version. Even if a data subject were successful in contacting 
the owner of a node, the latter would not be able to verify whether the personal data of a 
data subject has been processed. Off-chain storage can again facilitate GDPR compliance 
in relation to transactional data but not public keys.59 This is all the more true when a 
governance body is established to oversee the permissioned network. 
 
7. The right to erasure 
 
According to Jan Philipp Albrecht, the former member of the European Parliament who 
shepherded the GDPR through the legislative process, the administratively easy exercise 
of the right to be forgotten “is where blockchain applications will run into problems and 
will probably not be GDPR compliant."60 It is however common ground that the right 
to be forgotten cannot be straightforwardly applied to BCT, as immutability is one of the 
essential features of blockchains.61 However, the insight has grown that there is no such 
thing as perfect immutability in blockchains. For instance, it is easy to undermine if all 
the participants in a chain decide to do so together.62 			
57  FINCK, supra note 42, at 20-21. 
58  Cf. id. at 21-22. 
59  Id. at 23 (relating to public blockchains). 
60  Quoted in David Meyer, Blockchain technology is on a collision course with EU privacy law, The Privacy Advi-
sor (Feb. 27, 2018), https://iapp.org/news/a/blockchain-technology-is-on-a-collision-course-with-eu-privacy-
law/ (last visited Sept. 17, 2018, 01:20 AM). 
61  FINCK, supra note 42, at 23-24; Grekov, supra note 14. 
62  Greenspan, supra note 10; see also Grekov, supra note 14. 	
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Furthermore, the principle of immutability can be circumvented by an off-chain or simi-
lar solutions. Personal data which is recorded in a referenced encrypted and modifiable 
database as opposed to the blockchain itself, may be deleted in line with Article 17 of the 
GDPR.63 
With respect to public keys, GDPR compliance is again more difficult to reach. Whether 
any of the several solutions that have been developed up to now can satisfy GDPR re-
quirements remains to be seen.64 Notwithstanding that, it seems to be worth mentioning 
that certain implementing acts of the EU member states have already directed themselves 
towards a softer version of the right to erasure. For instance, Section 35(1) of the German 
Federal Data Protection Act65 provides that the data subject shall not have the right to 
erasure and the controller shall not be obligated to erase personal data if the “erasure 
would be impossible or would involve a disproportionate effort due to the specific mode 
of storage and if the data subject’s interest in erasure can be regarded as minimal”.66 
 
C. Does BCT support the GDPR 
 
Despite the tension between technology and law outlined above, it comes not totally as a 
surprise that BCT is being increasingly considered as a mechanism to help control the use 
of personal data under the GDPR.67 The reason is that both initiatives are aligned on the 
principles of secured and self-sovereign data.68 A prominent example of this coincidence 
are the guiding principles of data protection by design and data protection by default. 
Article 25(1) of the GDPR requires data protection to be designed into the development 
of business processes for products and services. Specifically, the controller should have 
technical, procedural, and organizational measures - such as pseudonymization and en-
cryption - in place in order to meet the requirements of the GDPR. Being based on ad-
vanced encryption technologies, BCT can support the implementation of GDPR-com-
pliant solutions which also may be a reason for regulators and courts to look favorably at 
it.69 
 
			
63  FINCK, supra note 42, at 24; CINDY COMPERT, MAURIZIO LUINETTI, & BERTRAND PORTIER , BLOCK-
CHAIN AND GDPR, IBM WHITE PAPER, 3, (2018), https://public.dhe.ibm.com/com-
mon/ssi/ecm/61/en/61014461usen/security-ibm-security-solutions-wg-white-paper-external-61014461usen-
20180319.pdf (last visited Sept. 17, 2018, 01:20 AM). 
64  FINCK, supra note 42, at 24; but see Grekov, supra note 14. 
65  Federal Law Gazette I p. 2097. 
66  Cf. FINCK, supra note 42, at 26; BLOCKCHAIN BUNDESVERBAND, supra note 42, at 8. 
67  Cf., e.g., COMPERT, LUINETTI, & PORTIER, supra note 63; Mearian, supra note 52. 
68  COMPERT, LUINETTI, & PORTIER, supra note 63, at 2. 
69  FINCK, supra note 42, at 26, 30-31; COMPERT, LUINETTI, & PORTIER, supra note 63, at 6-7 (hinting at the 
example of the Estonian EHR system). 	
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V. CONCLUSION AND OUTLOOK 
 
In sum, BCT offers many benefits to patients, health care service providers, hospitals, 
medical researchers, caregivers, and other healthcare parties. It integrates the healthcare 
ecosystem by adding accountability and transparency, while preserving privacy and con-
fidentiality.70 This indicates at least partial concordance with the objectives of the GDPR. 
Thus, BCT can provide an alternative means of achieving the objectives of the GDPR.71 
Yet it is also equally true that there is a systemic tension between technology and privacy 
law. And without any doubt, some blockchains in healthcare, as currently designed,72 are 
incompatible with the GDPR. 
Considering that the GDPR was developed without taking BCT into account, it could at 
first glance be wise to amend it for blockchains.73 Such a revision of the GDPR would 
acknowledge the fact that BCT creates order without law and implements private regula-
tory frameworks (lex cryptographia).74 However, for the time being, there are hardly any 
signs of EU reform initiatives in that respect. The European Parliament’s Committee on 
Industry, Research and Energy (ITRE) passed a resolution outlining the benefits of 
adopting DLT on May 16, 2018, without explicitly requiring amendments to the 
GDPR.75 The ITRE only emphasized that “it is of outmost importance [for] the DLT 
uses to be compliant with the EU legislation on data protection” and calls on the Euro-
pean Commission and the European Data Protection Supervisor (EDPS) to provide for 
further guidance on this point. After all, one seems to have recognized the problem that 
there may be some risk that the EU closes itself off from the future of the internet with 
respect to BCT. The EU Blockchain Observatory and Forum that has been launched by 
the Commission with the purpose of mapping key initiatives, monitoring developments, 
and inspiring common actions held a workshop on June 8, 2018 to examine the clashes 
and correlations between BCT and GDPR, and to provide, as far as possible, some guid-
ance to technologists, lawyers, entrepreneurs, and citizens in that respect, thus echoing 
the ITRE’s resolution on DLT and BCT. The workshop discussed separately the topics 
of technical, governance, and legal solutions and came to the positive result that there are 
only a few questions left unanswered or on which no agreement could be reached. This 
indicates that the reform of the GDPR is not the silver bullet, especially since the mills of 
			
70  Cf., e.g., CZESCHIK & STAMBOLIJA, supra note 8, at 34-38. 
71  FINCK, supra note 42, at 29. 
72  See for examples and use cases of BCT in the healthcare system CZESCHIK & STAMBOLIJA, supra note 8, at 25-
31; NICHOL, supra note 8, at 115-47. 
73  Toth, supra note 50. 
74  PRIMAVERA DE FILIPPI & AARON WRIGHT, BLOCKCHAIN AND THE LAW: THE RULE OF CODE, 5 and pas-
sim (2018). 
75  European Parliament Committee on Industry, Research and Energy (ITRE), Motion for a resolution on dis-
tributed ledger technologies and blockchains: building trust with disintermediation, ITRE/8/10 - 
2017/2772(RSP) (Compromise Amendments). 	
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Brussels grind slowly. Rather, it seems to be the order of the day that regulators and offi-
cials and BCT parties and developers cooperate towards mutually acceptable solutions 
such as off-chain storage of personal data and technical work-arounds. Furthermore, the 
creation of a code of conduct for BCT in accordance with Article 40 of the GDPR might 
be useful.76 
Of course, the message that GDPR and BCT can co-exist holds also true for healthcare 
settings. Consequently, the question may arise what EU initiatives exist specifically for 
the health sector. The ITRE resolution notes that DLT allows citizens to control and have 
transparency on their health data, chose which of those data to share, including their use 
with insurance companies and the wider healthcare ecosystem, but stresses also the neces-
sity to protect the privacy of the sensitive health data.77 According to the European Com-
mission’s communication on “Enabling the digital transformation of health and care in 
the Digital Single Market; empowering citizens and building a healthier society”, pub-
lished on April 24, 2018, it is intended to monitor the implementation of the GDPR and 
the eIDAS Regulation78 with regard to health and to take account of emerging technolo-
gies such as blockchain in the context of cybersecurity.79 That makes sense, as in a decen-
tralized BCT ransomware attacks on hospitals etc. would become more difficult.80 Fur-
thermore, the Staff Working Document accompanying the Commission's communica-
tion expresses the expectation that new emerging cybersecurity solutions building on 
trusted DLT for protecting the access to personal health data such as BCT could play an 
essential role if implemented systematically across Europe as part of the national and EU 
level data and computation infrastructures for personalized medicine.81 However, this is 
insufficient in the light of the unsettled legal issues discussed above. Therefore, it remains 
to be hoped that the Commission, in its announced recommendation on the technical 
specifications for an EHR exchange format,82 will take the opportunity to clarify the ten-
sion-loaded relationship between BCT and GDPR, thereby creating greater legal cer-
tainty. 
 
			
76  BLOCKCHAIN BUNDESVERBAND, supra note 42, at 9. 
77  European Parliament Committee on Industry, Research and Energy (ITRE), supra note 75. 
78  Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic 
identification and trust services for electronic transactions in the internal market and repealing Directive 
1999/93/EC (OJ L 257 of 28.8.2014, p. 73). 
79  COM(2018) 233 final, 6. 
80  Gordon, Wright & Landman, supra note 5; SCHUMACHER, supra note 8, at 4. 
81  COMMISSION STAFF WORKING DOCUMENT, Accompanying the document Communication from the Com-
mission to the European Parliament, the Council, the European Economic and Social Committee and the 
Committee of the Regions on enabling the digital transformation of health and care in the Digital Single Mar-
ket; empowering citizens and building a healthier society, COM(2018) 233 final, SWD(2018) 126 final, 41. 
82  See COM(2018) 233 final, 7. 
	 COMPLIANCE  ELLIANCE  JOURNAL   |   VOLUME 4   NUMBER 2   2018 
PAGE  21 
DIGITAL HEALTH REGULATORY GAPS IN THE UNITED 
STATES 
Kirk J. Nahra & Bethany A. Corbin 
AUTHORS 
Kirk J. Nahra is a partner with Wiley Rein LLP in Washington, D.C., where he special-
izes in privacy and information security litigation and counseling. He is chair of the firm’s 
Privacy Practice and assists companies in a wide range of industries in analyzing and im-
plementing the requirements of privacy and security laws across the country and interna-
tionally. He provides advice on data breaches, enforcement actions, contract negotiations, 
business strategy, research and de-identification issues, and privacy, data security, and cy-
bersecurity compliance. He also works with insurers and health care industry participants 
in developing compliance programs and defending against government investigations into 
their practices. Kirk, a Certified Information Privacy Professional (CIPP/US), is a long-
time member of the Board of Directors of the International Association of Privacy Profes-
sionals, and serves on the Advisory Board for the Health Law Reporter, the Privacy and 
Security Law Report, and the Health Care Fraud Report. He has held leadership positions 
with various groups within the American Health Lawyers Association and the American 
Bar Association Health Law Section. He is rated by Chambers USA in the nation’s top-
tier of privacy attorneys. Kirk can be reached at: E-mail: knahra@wileyrein.com; Phone: 
(202) 719-7335; Twitter: @KirkJNahrawork.  
 
Bethany A. Corbin is a complex litigation and regulatory compliance attorney with Wiley 
Rein LLP in Washington, D.C. She represents health care, pharmaceutical, telecommuni-
cations, and technology clients in judicial and administrative proceedings. She is a Certified 
Information Privacy Professional (CIPP/US) and provides strategic advice to health care 
organizations concerning privacy and cybersecurity. In December, Bethany will obtain her 
Health Care LL.M. from Loyola University of Chicago, where she has focused her studies 
on the intersection of health care and technology, including the Internet of Medical Things. 
Bethany currently serves as the Young Lawyer Representative to the Cybersecurity and 
Data Privacy General Committee of the Tort, Trial, and Insurance Practice Section of the 
American Bar Association. Bethany can be reached at: E-mail: bcorbin@wileyrein.com; 
Phone: (202) 719-4418; Twitter: @BethanyACorbin. 
 
 
 
 
		 COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
KIRK J. NAHRA & BETHANY A. CORBIN   |   DIGITAL HEALTH REGULATORY GAPS IN THE UNITED STATES 
 
PAGE  22 
ABSTRACT 
Digital health in the United States is rapidly and continuously evolving to enhance patient 
care and revolutionize health care delivery. This technology offers substantial promise to 
both patients and providers, but lacks a comprehensive regulatory structure to ensure ade-
quate safety and privacy. While the Department of Health and Human Services, the Food 
and Drug Administration, and the Federal Trade Commission regulate portions of the 
digital health industry, their oversight is incomplete, with numerous digital health compa-
nies falling between the cracks and assuming an unregulated status. This article analyzes 
the state of digital health legal and regulatory oversight in the United States, discusses how 
state legislatures and industry organizations have worked to fill existing legal gaps, and 
presents strategies for encouraging compliance for unregulated entities. 
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I. INTRODUCTION 
 
The boundaries and applications of digital health are rapidly evolving. From wearable fit-
ness sensors to ingestible pills to Internet-connected pacemakers and insulin pumps, dig-
ital health has the potential to transform the health care sector and revolutionize patient 
care. The benefits from digital health are undeniable: patients can assume greater respon-
sibility for the management of chronic conditions while accessing medical care at their 
convenience and in their own homes.1 Technology-based health care can further reduce 
the costs of care and help address the physician shortage across America.2 These benefits 
are a significant incentive to increase the adoption of mobile and digital technology in the 
health care industry, and the rate of this adoption is only projected to increase.  
While digital health offers substantial promise, it suffers to some extent from a lack of 
comprehensive regulation. This regulatory gap presents potential concerns both for pa-
tients—who may not be provided with appropriate protections—and for the industry, 
which will see compliance, operational and strategic challenges in designing products that 
meet with existing standards, potential future regulation, and consumer and regulator ex-
pectations. Privacy laws in the United States are sectoral and patchwork in nature, and 
those related to health care have not been significantly revised to address technological 
innovation. Privacy and security for digital health applications are therefore in flux, with 
some subsections of the industry unregulated by federal law. This article analyzes the 
scope and gaps of health care privacy and security laws in the United States and discusses 
available privacy and cybersecurity frameworks that exist for unregulated health care ac-
tors. 
II. WHAT IS DIGITAL HEALTH? 
 
The term digital health, at its most basic, refers to the intersection of health care and the 
Internet. Digital technologies that fall within this category are broad, and may include 
mobile health (mHealth), health information technology (HIT), wearable devices, tele-
medicine, the Internet of Things (IoT), and personalized medicine.3 While these technol-
ogies serve different functions—for example, HIT includes electronic health records and 
e-prescribing whereas IoT concerns sensors that interact between humans and machines 
to collect relevant health care data for diagnosis and disease management—they share one 			
1  See U.S. DEP’T HEALTH & HUMAN SERVS., EXAMINING OVERSIGHT OF THE PRIVACY & SECURITY OF 
HEALTH DATA COLLECTED BY ENTITIES NOT REGULATED BY HIPAA 2 (2016), 
https://www.healthit.gov/sites/default/files/non-covered_entities_report_june_17_2016.pdf (last visited 
Aug. 20, 2018, 01:30 PM). [hereinafter HHS HIPAA OVERSIGHT REPORT] 
2  Jeff Lagasse, With Physician Shortage Looming, Hospitals Turn to Telehealth Tools, HEALTHCARE FINANCE 
(June 1, 2018), https://www.healthcarefinancenews.com/news/physician-shortage-looming-hospitals-turn-
telehealth-tools (last visited Aug. 20, 2018, 01:35 PM). 
3  Charlotte A. Tschider, Enhancing Cybersecurity for the Digital Health Marketplace, 26 (1), ANNALS HEALTH 
LAW 1, 4 (2017). 	
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fundamental overriding goal: to use technology as a method for improving health care 
and increase the access and quality of medical services.  
The advent and adoption of digital health has the potential to profoundly impact the 
health care economy over the next several decades. To date, the United States has spent 
approximately 18% of its Gross Domestic Product on health care every year, and this fig-
ure is expected to increase to 20% by 2025.4 Digital health, however, is simultaneously ex-
pected to grow by a compounded annual growth rate of 26% in the upcoming years, and 
is projected to top $379 billion by 2024.5 These anticipated technological developments 
in the health care space may increase pressure to create and implement lower-cost health 
care solutions and incentivize companies to continue developing digital health products.6 
Significant shifts in the delivery of health care could be witnessed over the next several 
years. 
III. DIGITAL HEALTH RISKS 
 
Although the benefits of digital health are undeniable, concerns exist regarding the pri-
vacy and security of data collected through digital technologies. Like all digital platforms, 
Internet-connected health care devices pose privacy and security risks for their users. First, 
digital health applications collect and store patient health data, which may contain ex-
tremely sensitive information. Without proper security safeguards, this personal data may 
be unlawfully accessed by unauthorized users, resulting in a breach of personal infor-
mation. Such a breach not only harms the business and reputation of the digital device 
manufacturer, but also exposes critically sensitive patient data. There is no shortage of bad 
actors attempting to access medical data. Indeed, health data is one of the most lucrative 
objects for sale on the black market, fetching higher prices than social security numbers 
and financial information.7 Thus, the traditional data breach risk that is present with any 
Internet technology is amplified in the health care context due to value-laden sensitive 
data.  
Second, device interoperability and network connectivity bring the possibility for new 
attack vectors and vulnerabilities.8 A network hosting interconnected devices exponen-
tially expands its attack surface such that a security flaw or breach in any device operates 
as a backdoor entry point into the entire system.9 These digital health devices weaken the 			
4  Id. at 3. 
5  Keith Speights, What Is Digital Health?, MOTLEY FOOL (May 9, 2017, 7:04 AM), https://www.fool.com/in-
vesting/2017/05/09/what-is-digital-health.aspx (last visited Aug. 20, 2018, 01:37 PM). 
6  Tschider, supra note 3, at 4. 
7  See generally PRESIDENT’S NAT’L SEC. TELECOMMUNICATIONS ADVISORY COMMITTEE, NSTAC REPORT 
TO THE PRESIDENT ON THE INTERNET OF THINGS ES-1 (Nov. 19, 2014), https://www.dhs.gov/sites/de-
fault/files/publications/NSTAC%20Report%20to%20the%20President%20on%20the%20Inter-
net%20of%20Things%20Nov%202014%20%28updat%20%20%20.pdf (last visited Oct. 23, 2018, 01:35 PM). 
8  Id. at 7. 
9  See id. at 1. 
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overall security of a medical IT network by their mere presence on the network, and fur-
ther create access points that must be monitored and evaluated by the organization’s tech-
nology team. Unauthorized access into a network further has the potential to compromise 
data integrity, which can negatively impact patient care and treatment plans.  
Finally, digital health offers a unique risk that is not present with all Internet-based plat-
forms: bodily harm. Digital health devices that are implanted into a patient’s body, such 
as a cardiac pacemaker, may use the Internet to receive signals or instructions from a health 
care provider. Hijacking a pacemaker could allow an unauthorized third party to manip-
ulate the device’s functionality and cause significant bodily harm or death. This same sce-
nario is present with digital insulin pumps, where device hijacking could alter the dose of 
insulin a patient receives.  
Thus, digital health presents privacy, security, and resiliency risks that must be addressed 
and mitigated. These risks are increasingly being discussed in public policy circles, with 
the widespread recognition that technology advances faster than policy. The result is a 
crucial gap between legal frameworks and technological reality that heightens the security 
and privacy risks associated with digital health technology. 
IV. DIGITAL HEALTH LEGAL & REGULATORY FRAMEWORKS 
 
Digital health in the United States does not exist in an unregulated environment. Rather, 
the United States has adopted a sectoral approach to privacy that vests regulatory author-
ity for the health care sector with three federal government agencies (in addition to po-
tential regulation in each of the states): The Department of Health and Human Services 
(HHS), the Food and Drug Administration (FDA), and the Federal Trade Commission 
(FTC). In terms of privacy and security, HHS’s Office for Civil Rights (OCR) plays a 
dominant role in its enforcement of the Health Insurance Portability and Accountability 
Act (HIPAA).10 HIPAA represents the main legal framework addressing privacy and se-
curity requirements for the health care industry, and its applicability to digital health tech-
nologies is the focus of this article. In addition to HHS, the FDA regulates the efficacy 
and safety of medical “devices”,11 and has proposed voluntary cybersecurity guidance for 
connected medical devices.12 Finally, the FTC has broad non-industry-specific enforce-
ment powers that stem from Section 5(a) of the Federal Trade Commission Act (FTC 
Act).13 Pursuant to the FTC Act, the FTC may regulate unfair and deceptive trade prac-
tices in or affecting commerce. While the FTC Act does not specifically mention privacy, 			
10  See HHS HIPAA OVERSIGHT REPORT, supra note 1, at 3. 
11  Medical Device Overview, U.S. FOOD AND DRUG ADMINISTRATION (last updated Sept. 14, 2018), 
https://www.fda.gov/forindustry/importprogram/importbasics/regulatedproducts/ucm510630.htm (last 
visited Aug. 28, 2018, 01:58 PM). 
12  See Postmarket Management of Cybersecurity in Medical Devices - Guidance for Industry and Food and Drug 
Administration Staff, U.S. FOOD & DRUG ADMINISTRATION (Jan. 22, 2016), https://www.fda.gov/down-
loads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm482022.pdf (last visited 
Aug. 28, 2018, 01:53 PM). 
13  See HHS HIPAA OVERSIGHT REPORT, supra note 1, at 3. 	
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the FTC has brought numerous cases under Section 5(a) alleging that companies have en-
gaged in deceptive acts by failing to adhere to their stated privacy policies and procedures. 
This article next considers the scope and gaps of these regulatory frameworks as applied 
to digital health technology, and discusses efforts by state legislatures to bridge these gaps. 
 
A. The Health Insurance Portability and Accountability Act: Scope & Applicability 
 
In 1996, Congress passed the Health Insurance Portability and Accountability Act to en-
hance the portability of health insurance coverage and reduce the administrative costs and 
burdens associated with health care delivery.14 Neither of these primary goals were di-
rected at privacy and security—instead, the privacy and security rules that resulted from 
the HIPAA law were not discussed in any substantive way in the HIPAA statute. Instead, 
when Congress failed to step in and create a privacy and security law, HHS (later supple-
mented by the Health Information Technology for Economic and Clinical Health Act 
(HITECH Act)), created federal regulatory protections for the privacy and security of 
certain health information in certain settings when held by certain entities—with the 
scope of these rules defined by the “non-privacy” goals of the HIPAA statute.15 The 
HIPAA Privacy Rule sets forth required limitations on the use and disclosure of pro-
tected health information (PHI),16 while the HIPAA Security Rule mandates administra-
tive, technical, and physical safeguards for electronic PHI.17 Essentially, HIPAA seeks to 
protect health information by prohibiting disclosures of information that are unlawful 
or unauthorized, and ensuring that applicable health care entities enact reasonable and 
appropriate security safeguards for the data they collect or store.  
While the scope of HIPAA appears broad, its privacy and security requirements apply 
only to health care organizations that qualify as “covered entities.”18 A covered entity is 
any health plan, health care provider, or health care clearinghouse, as those terms are stat-
utorily defined (again, driven by concerns about portability and administrative simplifi-
cation and not privacy or security).19 In 2009, the HITECH Act extended HIPAA’s pro-
visions to “business associates,” which include persons or organizations that perform cer-
tain functions on behalf of a covered entity involving the use or disclosure of PHI—es-
sentially, service providers to these covered entities where the services involve individual 
information.20 PHI, in turn, is defined as individually identifiable health information 			
14  Kirk J. Nahra, HIPAA Privacy and Security for Beginners, WILEY REIN (July 2014), 
https://www.wileyrein.com/newsroom-newsletters-item-5029.html (last visited Aug. 28, 2018, 01:55 PM). 
15  See id. 
16  See 45 C.F.R. § 164.502; DEP’T HEALTH & HUMAN SERVS. OFFICE FOR CIVIL RIGHTS, SUMMARY OF THE 
HIPAA PRIVACY RULE 1 (last revised May 2003), https://www.hhs.gov/sites/default/files/privacysum-
mary.pdf?language=en (last visited Aug. 28, 2018, 02:05 PM). 
17  See 45 C.F.R. §§ 164.308-312. 
18  See, e.g., 45 C.F.R. § 164.502. 
19  Id. § 160.103; Nahra, supra note 14. 
20  See 45 C.F.R. § 160.103. 	
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that a covered entity or its business associate holds or transmits in any form or media.21  
The foundational principle of HIPAA is that a covered entity or business associate may 
not use or disclose PHI except as either expressly permitted in the Privacy Rule, or as au-
thorized by the patient in writing. A covered entity is only required to disclose PHI in 
two circumstances: (1) to the patient herself when requested; and (2) to HHS as part of a 
compliance investigation or enforcement action.22 A covered entity is permitted—but 
not required—to disclose PHI without first obtaining the patient’s authorization (with 
presumed consent under the HIPAA Privacy Rule) for the “core” purposes of the health 
care system—treatment, payment, and performance of health care operations (TPO) (es-
sentially the administrative operations of a health care business).23 There also are various 
“public policy” rationales for the use and disclosure of PHI.  All other uses and disclosure 
of PHI not expressly permitted by the Privacy Rule require an individual’s written au-
thorization. 
 
B. HIPAA and Digital Health Technology: Assessing the Gaps 
 
Although HIPAA may appear at first blush to be a comprehensive privacy framework for 
the health care industry, it has significant gaps and limitations when applied to digital 
health technology.24 First, HIPAA’s protections only extend to digital health actors that 
qualify as covered entities. When HIPAA was originally drafted, HHS only had authority 
to create a privacy rule applicable to covered entities such as health care providers and 
health insurers.25 This means organizations that do not qualify as covered entities or busi-
ness associates typically have no obligation to comply with HIPAA’s requirements. For 
example, a company manufacturing a fitness tracker that collects basic health information 
such as height, weight, and biometric data, would not be subject to HIPAA’s regulations 
because the company provides this product directly to an individual consumer without 
the involvement of a doctor or health insurer. The company does not provide or pay the 
cost of an individual’s medical care, does not provide medical services, and does not pro-
cess non-standard data received from another entity into a standardized format (e.g., bill-
ing companies, community health management information systems, etc.). In other 
words, the company is not a covered entity (i.e., it is not a health plan, a health care pro-
vider, or a health care clearinghouse). Thus, this company would fall outside the bounds 
of HIPAA’s privacy and security regulations despite the fact that it collects sensitive 
health data.  			
21  Id. 
22  Id. § 164.502; Nahra, supra note 14. 
23  45 C.F.R. § 164.502; Nahra, supra note 14. 
24  See HHS HIPAA OVERSIGHT REPORT, supra note 1, at 20; Kirk J. Nahra, What Closing the HIPAA Gaps 
Means for the Future of Healthcare Privacy, HITECH ANSWERS (Nov. 9, 2015), 
https://www.hitechanswers.net/what-closing-the-hipaa-gaps-means-for-the-future-of-healthcare-privacy-2/ 
(last visited Aug. 28, 2018, 03:14 PM). 
25  Nahra, supra note 24. 	
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Second, HIPAA only protects and regulates PHI. PHI refers to individually identifiable 
health information (including demographic data) that relates to a person’s physical or 
mental health, the provision of health care services to that individual, or payment for 
health care services, and that identifies the individual or would provide a reasonable basis 
for identification.26 Health care data that does not satisfy this definition may be collected, 
used, and disclosed by a company without running afoul of HIPAA. For example, where 
health information has been de-identified or aggregated without disclosing individual 
identifiers, it does not constitute PHI and may be disclosed without an individual’s con-
sent or authorization.27 In State ex rel. Cincinnati Enquirer v. Daniels, for instance, the 
Ohio Supreme Court held that the Cincinnati Enquirer could obtain copies of lead-con-
tamination notices issued by the Cincinnati Health Department.28 The court found that 
the notices did not reveal PHI even though they referenced an unnamed child whose 
blood test showed an elevated lead level.29 Similarly, guidance on HHS’s website notes 
that merely reporting the average age of health plan members is not PHI because the ag-
gregated data does not identify any individual plan member.30 
These limitations in HIPAA’s scope present large regulatory gaps when applied to the 
digital health sector (except in those situations where a digital health product is provided 
directly by a HIPAA covered entity or in a business partnership with a provider or in-
surer). Today, with minor exceptions, most digital health companies do not qualify as 
covered entities or business associates, and remain unregulated by HIPAA. Similarly, 
some of these organizations may collect sensitive health data that does not qualify as PHI. 
When either of these scenarios occurs, the digital health company is not subject to 
HIPAA’s privacy and security regulations, and may operate with significantly less federal 
oversight. The regulatory scheme created by HIPAA focuses largely on which entity holds 
the data, and not on the nature or sensitivity of the information being collected. This, in 
turn, allows a significant portion of the digital health sector to avoid compliance with 
these crucial HIPAA privacy and security standards. 
 
C. FDA, FTC, and Medical Device Regulation 
 
In addition to HHS’s oversight of HIPAA, the Food and Drug Administration assumes 
a key role in the regulation of medical devices, including Internet-connected medical tech-
nology. The FDA’s role, however, is limited primarily to ensuring the safety and efficacy 
of certain classifications of devices, and not all mobile or digital technologies will trigger 			
26  Id. § 160.103. 
27  Id. § 164.502(d). 
28  844 N.E.2d 1181 (Ohio 2006). 
29  Id. at 523; Cuyahoga Cty. Bd. of Health v. Lipson O’Shea Legal Group, 50 N.E.3d 499, 501 (Ohio 2016) 
30  Guidance Regarding Methods for De-Identification of Protected Health Information in Accordance with the 
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, DEP’T HEALTH & HUMAN 
SERVS., https://www.hhs.gov/sites/default/files/ocr/privacy/hipaa/understanding/coveredentities/De-
identification/hhs_deid_guidance.pdf (last updated Nov. 6, 2015). 	
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FDA scrutiny.31 Moreover, FDA regulations are not typically geared towards protecting 
patient privacy or security. While the FDA has released voluntary guidance “for managing 
postmarket cybersecurity vulnerabilities for marketed and distributed medical devices,” 
this guidance is not mandatory.32 The FDA does not require cybersecurity testing for any 
device, and relies on the device manufacturer to perform any voluntary security testing.33 
Further, the FDA does not regulate device privacy, leaving such devices to be covered (if 
at all) by HIPAA.  
Similarly, the Federal Trade Commission has played a crucial part in privacy policy, en-
forcement, and best practices since the 1970s.34 The FTC is an independent federal agency 
responsible for protecting consumers and promoting competition. While the FTC is not 
specific to health care, its regulatory authority extends to unfair and deceptive acts or prac-
tices, which may occur in the health care industry.35 In particular, the FTC can bring en-
forcement actions to halt violations of privacy and security laws. The FTC has brought 
more than 500 enforcement actions to protect consumer privacy, and these actions ad-
dress a wide range of issues, including spyware, mobile devices, file sharing, and spam.36 
Cases may also involve non-adherence to a privacy policy. Similarly, the FTC has initiated 
over 60 cases since 2002 against companies that failed to adequately protect consumers’ 
personal data.37 In this manner, FTC’s authority is broad, but is not directed at preventing 
or regulating privacy and security standards in the health care industry. Instead, FTC acts 
as a watchdog to enforce existing privacy and security standards, but does not create those 
standards. Thus, while FTC may enforce existing privacy and security laws in the digital 
health context, it does not address legislative gaps that may leave digital health technology 
unregulated. 
 
 
 			
31  See Kirk J. Nahra, New York Attorney General Addresses Key Health Care Privacy Gaps, WILEY REIN (Apr. 
2017), https://www.wileyrein.com/newsroom-newsletters-item-April_2017_PIF-NY_AG_Ad-
dresses_Key_Health_Care_Privacy_Gaps.html (last visited Aug. 28, 2018, 03:15 PM). 
32  Postmarket Management of Cybersecurity in Medical Devices - Guidance for Industry and Food and Drug 
Administration Staff, U.S. FOOD & DRUG ADMINISTRATION 4 (Dec. 28, 2016), https://www.fda.gov/down-
loads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm482022.pdf (last visited 
Aug. 28, 2018, 01:43 PM). 
33  Adam Brand, Closing the Gap in Medical Device Cybersecurity, PROTIVITI (Jan. 3, 2018), https://blog.protiv-
iti.com/2018/01/03/closing-gap-medical-device-cybersecurity/ (last visited Aug. 28, 2018, 01:43 PM). 
34  Protecting Consumer Privacy and Security, FEDERAL TRADE COMMISSION, https://www.ftc.gov/news-
events/media-resources/protecting-consumer-privacy-security (last visited Sept. 29, 2018, 04:33 PM). 
35  See Privacy & Data Security Update:2017, FEDERAL TRADE COMMISSION, at 1 (Jan. 2017 – Dec. 2017), 
https://www.ftc.gov/system/files/documents/reports/privacy-data-security-update-2017-overview-commis-
sions-enforcement-policy-initiatives-consumer/privacy_and_data_security_update_2017.pdf (last visited 
Sept. 29, 2018, 04:19 PM). 
36  Id. at 1-2. 
37  Id. at 4. 	
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D. State Regulatory Frameworks 
 
As the gaps associated with federal legislation become more apparent, states have begun 
stepping in to ensure comprehensive privacy and security standards apply to digital 
health. In March 2017, for example, New York Attorney General Eric Schneiderman an-
nounced that his office settled three cases with various mobile health applications for in-
sufficient or inappropriate privacy practices, and misleading privacy and security claims.38 
In bringing these cases, New York acted to fill a regulatory gap in FDA oversight—these 
digital health devices had not triggered FDA review—and the HIPAA Privacy Rule.39 
Specifically, although digital health devices were being used in these cases, the companies 
did not qualify as covered entities and, therefore, no federal privacy structure governed 
these organizations. The New York Attorney General stepped in to ensure privacy pro-
tections would be applicable to these digital health applications despite the absence of a 
comprehensive federal regulatory structure.40 Such action signifies a potential shift to-
ward “regulation through enforcement,”41 which states may begin to use more frequently 
if federal privacy and security standards are not properly updated. 
In addition to New York’s enforcement action, states have also begun implementing leg-
islation to patch the holes in federal regulations. The most recent and innovative action 
by a state is S.B. 327, a cybersecurity bill governing Internet of Things devices in Califor-
nia.42 California Governor Jerry Brown recently signed this bill into law, making it the 
first state in the nation to adopt IoT legislation. This new law, which becomes effective 
on January 1, 2020, will mandate that any manufacturer or developer of a “smart” de-
vice—including connected health devices—ensure that the product is equipped with rea-
sonable security features to protect the device and the information it houses.43 Advocates 
of the bill hope that the new law will focus nationwide attention on the issue of IoT se-
curity, which extends beyond state boundaries.  
Legislation, such as S.B. 327, is intended to bridge gaps in federal regulatory frameworks. 
Whereas a digital health company may escape HIPAA’s grasp because it does not qualify 
as a covered entity, the company would still be subject to minimum privacy and security 
standards if it conducts business in California. The goal of such legislation is to minimize 
opportunities for organizations to collect sensitive data without being subject to some 
form of regulatory structure simply because the pace of technological innovation out-
paces policy discussions.  
As the nation reacts to S.B. 327, it will be interesting to observe whether other states im-
plement comparable legislation, and whether upcoming bills will spur the federal legisla-
ture to create a comprehensive regulatory framework. Addressing privacy and security for 			
38  Nahra, supra note 31. 
39  Id. 
40  Id. 
41  Id. 
42  Senate Bill No. 327 (Cal. Sept. 28, 2018), available at https://leginfo.legislature.ca.gov/faces/billNavCli-
ent.xhtml?bill_id=201720180SB327 (last visited Sept. 29, 2018, 03:19 PM). 
43  Id. 
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digital health and other Internet-connected devices on a state-by-state basis risks incon-
sistent standards and approaches, which could make it more difficult for digital health 
companies to determine their obligations, duties, and responsibilities. Comprehensive 
federal legislation could add consistency and predictability to privacy and security stand-
ards in digital health. However, until the federal legislature takes action, such standards 
will have to be developed and enforced by states and industry organizations. 
V. THE DANGERS OF NON-REGULATION 
 
Inconsistent or non-regulation of health care entities presents numerous risks that are un-
acceptable to both organizations and patients. Importantly, the lack of a mandatory reg-
ulatory regime may lead some digital health companies to avoid basic privacy and security 
practices altogether and endanger patient data. In many instances, economic incentives 
can cause digital health companies to push their devices to market with little consideration 
for security measures.44 These devices, in turn, may be particularly susceptible to hacking, 
which can lead to the unauthorized acquisition of patient health data. Moreover, these 
devices may operate on larger health care networks and create backdoor entry points to 
accessing data from an entire health system that is otherwise secure. Such devices not only 
jeopardize the confidentiality and integrity of their own users’ data, but also have the po-
tential to create widespread breaches of health data at larger institutions.  
Moreover, consumers are often not equipped to understand the difference between cov-
ered entities and non-covered entities and how this distinction drives digital health com-
pliance. Instead, consumers may assume that their sensitive health data is protected and 
that adequate security measures will protect them from harm despite a contrary reality. 
The current regulatory framework assigns consumers the hardship of understanding the 
applicability of complex legal regulations to protect their own privacy and security.  
Consumers, however, are not the only group harmed by gaps in digital health regulation. 
Digital health innovators and entrepreneurs are also adversely affected. In particular, hav-
ing separate rules that apply to covered and non-covered entities can create confusion 
among tech innovators as to whether their products would be regulated under federal 
frameworks. This uncertainty may result in hesitant investors, which can delay or stifle 
technological innovation in the health care industry.45 Further, a breach from lax security 
practices may cause immense reputational damage to the digital health company. 
VI. ENCOURAGING COMPLIANCE 
 
While federal regulatory compliance may not be mandatory for a large portion of the dig-
ital health industry, digital health companies should nonetheless ensure they are adhering 
to adequate privacy and security standards. The reason for this is, at a minimum, three-			
44  See Paul Merrion, DHS Warns Insecure Internet of Things Could Spur Product Liability Lawsuits, CQ ROLL 
CALL WASH. DATA PRIVACY BRIEFING (Nov. 16, 2016), available at 2016 WL 6774799. 
45  Alexis Guadarrama, Mind the Gap: Addressing Gaps in HIPAA Coverage in the Mobile Health Apps Indus-
try, 55 (4) HOUSTON LAW REVIEW 999, 1017 (2018). 
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fold. First, consumers expect minimum privacy and security standards to be associated 
with their products, and can negatively impact a company’s market share if that company 
fails to satisfy consumer expectations. Second, it is inevitable that unregulated digital 
health companies will eventually be subject to a privacy and security regulatory scheme. 
While the form of this comprehensive regulatory framework is currently unknown, the 
risks associated with unregulated digital health products are too great to leave this indus-
try unattended. This has become evident with California’s implementation of S.B. 327—
if the federal legislature does not act, states will. Companies that delay implementing basic 
privacy and security standards now will be adversely impacted if a new regulatory struc-
ture takes effect. Moreover, it is likely that regulations for digital health companies will 
mirror privacy and security best practices in effect today. Digital health companies have 
the opportunity now to build strong compliance programs and privacy policies, which 
will result in a smooth transition under future regulations.  
Finally, by participating in the privacy and security dialogue today, digital health compa-
nies can help establish the standards and requirements for future regulations that will 
govern their industry. Public-private stakeholder participation is actively encouraged as 
policymakers think through how to regulate new technologies without stifling innova-
tion.46 By engaging with privacy and security concerns today, digital health companies 
can advocate for regulations that will promote their business interests while protecting 
consumer data.  
The question then becomes which frameworks should digital health companies adhere to 
when implementing privacy and security standards? The obvious choice is HIPAA, par-
ticularly for data security, even though its requirements are not yet mandatory for a sig-
nificant portion of the digital health industry. As an established framework governing 
health care privacy and security compliance, HIPAA contains sufficient flexibility to 
adapt to varied circumstances and organizations, including digital health. By voluntarily 
complying with HIPAA (or trying to meet its standards where they make sense for the 
business), digital health companies can ensure they are implementing best practice stand-
ards in effect for the health care industry. Such compliance will also create consistency 
across the health care sector and avoid inconsistent application of privacy and security 
rules. Consumers will be better able to gauge their privacy and security rights and reme-
dies with uniform implementation of HIPAA’s rules. Indeed, numerous experts have 
counseled in favor of expanding HIPAA’s reach to the digital health industry.47 The 
downside to voluntary compliance with HIPAA, however, is not only the costs associated 
with implementing adequate standards, but also the concern that the traditional TPO 
model of disclosure under HIPAA may not fit well with consumer facing products. 
An alternative is for digital health companies to implement industry-created cybersecurity 			
46  See Bethany Corbin & Megan Brown, Partnerships Can Enhance Security in Connected Health and Beyond, 
CIRCLEID (Dec. 14, 2017, 8:30 AM), http://www.circleid.com/posts/20171213_partnerships_can_enhance_se-
curity_in_connected_health_and_beyond/ (last visited Sept. 30, 2018, 05:19 PM). 
47  See Mary Butler, Is HIPAA Outdated? While Coverage Gaps and Growing Breaches Raise Industry Concern, 
Others Argue HIPAA is Still Effective, 88 J. AHIMA 14 (2017), 
http://bok.ahima.org/doc?oid=302073#.W6TW0a2ZP-Y (last visited Sept. 29, 2018, 03:19 PM). 	
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frameworks. Many HIPAA-regulated entities also follow one or more security frame-
works developed by industry professionals to enhance the security and availability of pa-
tient data. Numerous frameworks exist, enabling digital health companies to adopt the 
framework that best meets their organizational structure and needs. The 2018 HIMSS 
Report surveyed health care organizations and identified the five primary security frame-
works in use throughout the health care industry today:48 (1) National Institute of Stand-
ards and Technology (NIST);49 (2) Health Information Trust Alliance (HITRUST);50 
(3) Center for Internet Security (CIS) Critical Security Controls;51 (4) International Or-
ganization for Standardization (ISO);52 and (5) Control Objectives for Information and 
Related Technologies (COBIT). 53  Adoption of one of these voluntary cybersecurity 
frameworks will assist digital health companies with remaining up-to-date on cybersecu-
rity hygiene and can offer insight into guarding against common security threats affecting 
the industry 
VII. CONCLUSION 
 
Digital health represents an advantageous development to enhancing patient wellness and 
health care delivery in the United States. With the potential to lower medical costs and 
serve broader patient populations, digital health is only projected to grow in the coming 
years. As this technological frontier develops, it is crucial that federal regulations evolve 
to safeguard patient privacy and security. The current regulatory framework for the 
health care industry contains significant gaps that exclude a majority of digital health com-
panies from necessary federal oversight in their data collection practices. As Congress con-
siders the most effective method to remedy these gaps, digital health companies should be 
proactive in their approach to privacy and security, including voluntary compliance with 
HIPAA and industry-created cybersecurity frameworks. Such proactive behavior not 
only promotes consumer confidence in the digital health company, but also enables the 
company to contribute to the dialogue on best practice standards for the digital health 
industry. 
			
48  HIMSS, 2018 Himss Cybersecurity Survey, 18 (2018), 
https://www.himss.org/sites/himssorg/files/u132196/2018_HIMSS_Cybersecurity_Survey_Final_Re-
port.pdf (last visited Sept. 28, 2018, 02:49 PM). 
49  National Institute of Standards and Technology, Framework for Improving Critical Infrastructure Cybersecu-
rity Version 1.1 (Apr. 16, 2018), https://nvlpubs.nist.gov/nistpubs/CSWP/NIST.CSWP.04162018.pdf (last vis-
ited Sept. 28, 2018, 03:19 AM). 
50  CSF Version 9.1, HITRUST, https://hitrustalliance.net/hitrust-csf/ (last visited Sept. 21, 2018, 10:35 AM). 
51  Download the CIS Controls V7 Today, CENTER FOR INTERNET SEC., https://learn.cisecurity.org/20-con-
trols-download (last visited Sept. 21, 2018, 11:03 AM). 
52  ISO 27001 - Information security management systems, INTERNATIONAL ORGANIZATION FOR STANDARD-
IZATION, https://www.iso.org/isoiec-27001-information-security.html (last visited Sept. 21, 2018, 10:42 AM). 
53  COBIT 4.1: Framework for IT Governance and Control, ISACA, https://www.isaca.org/knowledge-cen-
ter/cobit/Pages/Overview.aspx (last visited Sept. 21, 2018, 10:44 AM). 
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I. INTRODUCTION 
 
Digitization in the health sector has been a perennial issue in legal and medical expert dis-
cussions for several years now. The respective legislative progress can be considered rather 
sluggish, not least because of the controversial picture of opinions. Despite the high num-
ber of supporters in favor of digitization in health care, the amount of critics and skeptics 
is decreasing slowly. 
 
The supporters of remote treatment see an advantage for improving health care, especially 
regarding the demographic changes and the shortage of physicians, not only in rural areas. 
Moreover, due to the possibility of offering short-term consultations, improvements in 
quality of medical services are predicted. Not only the fully employed patient appreciates 
remote treatment as a huge timesaver. Besides, the risk of infection in the physician’s of-
fice can be reduced. Critics of (exclusive) remote treatment fear that the trustful relation 
between patient and physician might suffer from the lack of personal contact. An increase 
of diagnostic errors is predicted due to a restriction in the possibilities of perception and 
cognition. Last but not least, the “new” digital methods of data transfer imply a higher 
risk for the highly sensitive patient health data2. 
 
The physicians’ professional code in Germany reflected these concerns and the require-
ments for patient safety in its former version, valid until the decision of the 121st German 
Medical Association in May 2018. In contrast, neighboring countries such as Switzerland 
have already permitted exclusive remote treatment – without being swamped with re-
proaches of medical malpractice. Foreign providers of remote treatment have already es-
tablished themselves on the German market by requisitioning German physicians3. This 
shows that a “head-in-the-sand-policy” can have counterproductive effects on digitiza-
tion. The decision of the German Medical Association in May 2018 on opening the ban 
of exclusive remote treatment is therefore to be welcomed. 
 
Needless to say that despite all the euphoria about digital progress and digital freedoms, 
the patient health data concerned, which are particularly sensitive in relation to funda-
mental rights, should not be neglected. However – and this aspect is often overlooked – 
data protection requirements are applicable not only for remote treatment, but also in 
every “conventional” physician’s office. Regarding the possibility of fast transfer of large 
datasets and the resulting increased risk potential4, data protection becomes more virulent 			
2  For advantages and disadvantages cf. Peter Kalb, Rechtliche Aspekte der Telemedizin (Legal aspects of telemed-
icine), 8, GESR, 481, 483 (2018). 
3  Cf. speech of the president of the German Medical Association and the German Physicians’ Board, Prof. Dr. 
Frank Ulrich Montgomery, Opening of the 121st German Physicians’ Board in the Steigerwaldstadion Erfurt 
on the 8th of May 2018, 9, https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-
Ordner/121.DAET/Eroeffnungsrede_Prof._Montgomery.pdf (last visited Sept. 28, 2018). 
4  Already: Wilfried Berg, Telemedizin und Datenschutz (Telemedicine and data protection), 8, MEDR, 411, 413 
(2004) with further references. 
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in the context of telemedicine. 
II. LEGAL POSSIBILITIES OF REMOTE TREATMENTS IN GERMANY 
 
The revised version of § 7 para. 4 sentence 3 MBO-Ä now reads as follows: “Exclusive 
consultation or treatment via communication media is permitted in individual cases if 
this is medically justifiable and the necessary medical care is maintained, in particular 
through the way in which findings are made, consultation, treatment and documentation 
are provided, and the patient is also informed about the special features of exclusive con-
sultation and treatment via communication media.”. In the future, patients should be 
provided with medical care that corresponds to the recognized state of medical 
knowledge, which includes the further development of telemedicine, digital, diagnostic 
and other comparable possibilities, without establishing a model of primary telemedicinal 
treatment. The personal doctor-patient contact should thus continue to be regarded as 
the “gold standard” of medical treatment5. But what does the change of the MBO-Ä mean 
for physicians? How is the new regulation to be interpreted? And: How does it fit in with 
other legal systems in force? 
 
A. Physicians’ Professional Law 
 
The reformulation of the MBO-Ä alone does not change anything for the attending phy-
sician. The MBO-Ä itself has no legal norm quality and therefore needs to be transposed 
into the professional regulations of the Federal States’ Chambers of Physicians. Although 
the MBO-Ä is not legally binding, it nevertheless serves as a guidance for the Federal 
States’ Chambers of Physicians, so that the earlier prohibition of exclusive remote treat-
ment (old § 7 para. 4 MBO-Ä) has also been adopted analogously by all Federal States’ 
Chambers of Physicians in their professional regulations. Today, however, this no longer 
applies without restrictions. In summer 2016, the State Chamber of Physicians in Baden-
Württemberg has already changed its professional regulations and approved remote treat-
ment of Baden-Württemberg patients by Baden-Württemberg physicians for model pro-
jects. This year, the Federal States’ Chambers of Physicians of Schleswig-Holstein and Sax-
ony have also legitimized the exclusive remote treatment in cases of medical justifiability 
by amending the respective Professional Code of Conduct.  
Finally, the representatives’ meeting of the Rhineland-Palatinate State Chamber of Phy-
sicians – very recently – decided on 20th September 2018 on a corresponding new regula-
tion of the Professional Code of Conduct. 
 
It can be assumed that other regional Chambers of Physicians will amend their profes-
sional regulations in accordance with the new provisions of § 7 para. 4 MBO-Ä. On the 			
5  Synopsis of the changes in § 7 Abs. 4 MBO-Ä (remote treatment), https://www.bundesaerztekam-
mer.de/fileadmin/user_upload/downloads/pdf-Ordner/MBO/Synopse_MBO-AE_zu_AEnder-
ungen____7_Abs._4.pdf (last visited Sept. 28, 2018). 	
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other hand, in May 2018 the Saarland Chamber of Physicians – following the resolution 
of the 121st German Medical Association – expressly spoke out against a relaxation of the 
prohibition of exclusive remote treatment6, with the result that the professional law will 
probably be fragmented in this respect. In the context of remote treatment, the question 
of the applicable professional law will therefore soon arise.  
 
The physician is a compulsory member of the regional Chamber of Physicians in whose 
district he practices his profession. He is therefore also subject to their professional code 
of conduct. In the case of a “normal” visit to the doctor, it is clear that the doctor exercises 
his profession at the office. But does this also apply if the doctor offers online video con-
sultation hours from his practice, during which he treats patients from other chamber 
districts? There is much to be said in favor of continuing to determine the physician’s 
place of business as the place where he exercises his profession7. A different understanding 
would lead, in particular, to considerable practical difficulties. Based on the patient’s ac-
tual whereabouts during treatment – which could alternatively be taken as a basis – the 
attending physician would possibly become a compulsory member of a large number of 
regional chambers of physicians, which in turn could lead to an unreasonable burden on 
the exercise of the physician’s profession. Ultimately, determining the patient’s actual 
whereabouts could also mean unreasonable additional work for the doctor. All this would 
in any case make remote treatment extremely unattractive from a medical point of view, 
so that the desired progress would not be achieved. 
 
B. New wording of § 7 para. 4 of the Model Professional Code of Conduct   
(MBO-Ä) 
 
According to § 7 para. 4 sentence 3 MBO-Ä in its new wording it should definitely be 
decisive in the future whether the attending physician considers the exclusive remote 
treatment to be medically justifiable in the individual case. But when is remote treatment 
medically justifiable? And what defines an individual case? There is no legal definition for 
this. 
It is safe to assume that the previously permitted options of remote treatment will also be 
permitted under the new regulation8. However, the new regulation is expressly intended 			
6  Cf. Andeas Kindel, Fernbehandlung, Saar-Ärzte fürchten Kontrollverlust (Remote treatment, Saar-physicians 
fear loss of control), ÄRZTEZEITUNG ONLINE (May 2 2018), https://www.aerztezeitung.de/politik_gesell-
schaft/berufspolitik/article/963095/fernbehandlung-saar-aerzte-fuerchten-kontrollverlust-telemedizin.html 
(last access Sept. 28, 2018). 
7  The question of the professional law also arises in particular with regard to the cross-border telemedical activ-
ities of physicians who are established in another EU member state. 
8  § 7 para. 4 MBO-Ä (old version) has not standardized a general prohibition of remote treatment measures, 
rather only diagnosis and therapy recommendation for unknown patients via print and communication media 
– i.e. in the context of the first contact – should be completely prohibited by this law, cf. in this regard: Notes 
and explanations of the Federal Chamber of Physicians on § 7 para. 4 MBO-Ä (remote treatment), 11.12.2015 
https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/Recht/2015-12-
11_Hinweise_und_Erlaeuterungen_zur_Fernbehandlung.pdf (last visited Sept. 28, 2018); Anna Kristina 	
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to permit other forms of remote treatment, in particular the initial contact via means of 
communication.  
 
In order to determine the regulatory content, the view taken here is that the principle of 
freedom of medical treatment recognized by the highest court9 and the case-law on med-
ical liability can be relied upon. Medical freedom of therapy means here that the physician 
can in principle choose the examination and treatment methods – among the permissible 
treatment methods – freely, he thus possesses a discretionary and judgmental scope in this 
respect10. This means that the proper course of medical action is determined exclusively 
by whether the physician has made justifiable decisions about diagnostic and therapeutic 
measures using “the medical knowledge and experience required from him in the specific 
case and has carefully implemented these measures”11. 
 
Correctly, the physician must therefore ask in relation to the intended purpose what 
“form of depth of the physicians’ perception of the patient is necessary for the physician 
for standard treatment”12. The physician must therefore assess the risks of remote treat-
ment on his own responsibility on a case-by-case basis, i.e. in relation to the treatment and 
the patient. As soon as the doctor considers a personal visit of the patient to be indicated, 
he has to point this out to the patient and interrupt the remote treatment. As with any 
other therapy recommendation, it is then up to the patient to actually follow this up. 
 
If the physician decides to carry out remote treatment, even though this was not medically 
justifiable in the individual case, this violation of professional duties can lead to civil lia-
bility.  
The choice of a medically unjustifiable form of therapy can quickly be regarded as a gross 
medical malpractice in a lawsuit. 
 
The physician should also pay special attention to patient information, because in the 
context of remote treatment the physician must also inform about the special features of 
consultation and treatment exclusively via communication media. The obligatory con-
tent of this information is not defined, but can also be determined according to the tradi-
tional principles. However, it is recommended to expressly point out to the patient that 
not all diagnostic possibilities, such as palpating, can be used in the context of remote 
treatment – even if this is likely to be self-explanatory to the patient on a regular basis. 
This recommendation applies at least as long as there is no highest court jurisdiction on 			
Kuhn, Grenzen der Digitalisierung der Medizin de lege lata und de lege ferenda (Limits to digitization in 
health care de lege lata and de lege ferenda), 12, GESR, 748 (2016). 
9  Cf. BGH (German Federal Supreme Court), decision dated Sept. 22, 1987 – VI ZR 238/86, NJW 1988, 763, 
764. 
10  LAUFS/KERN, HANDBUCH DES ARZTRECHTS (MANUAL OF MEDICAL LAW), § 97 Rn. 36, (4th ed. 2010). 
11  BGH (German Federal Supreme Court), decision dated March 10, 1987 – VI ZR 88/86, NJW 1987, 2291, 2292. 
12  Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsaufnahme zur aktuellen Entwicklung 
(Telemedicine and ban of remote treatment – an inventory of the latest developments), 36, MEDR, 384, 386 
(2018). 
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this, because in a medical liability lawsuit the physician has to prove the correctness of the 
information. The special information and consent should also be included in the patient 
documentation. 
 
C. Federal regulations 
 
The amendment of the MBO-Ä or the professional law alone is not sufficient to reason-
ably integrate remote treatment into the system of medical care. Rather, an extensive ac-
tion by the legislator is required here. Some statutory provisions currently stand in the 
way of an effective offer of remote treatment services – this is illustrated by the example 
of the provisions of § 9 of the German Act on Advertising of Medicinal Products (HWG) 
and § 48 of the German Medicinal Products Act (AMG). 
 
1. § 9 German Act on Advertising of Medicinal Products (HWG) 
 
According to § 9 HWG, advertising for the recognition or treatment of diseases, suffer-
ings, bodily injuries or pathological complaints that are not based on the physician’s own 
perception of the patient is not permitted. Although it is not the remote treatment itself 
that is prohibited, but only the advertising for the same, the provision under the law on 
therapeutic product advertising nevertheless stands in the way of an appropriate offer of 
remote treatment services. There is no distinction according to whether distance treat-
ment is permissible or inadmissible under professional law, so that the wording of the 
provision is clear. It is well known that the wording represents the limit of any interpre-
tation. Any interpretation to the effect that forms of remote treatment permitted under 
professional law are not covered by the advertising ban cannot be made for this and other 
reasons13. The medical professional codes of conduct are established as statutory law in 
the hierarchy of norms below formal statutory law. The result of an interpretation cannot 
be that the formal-legal prohibition norm of § 9 HWG is leveraged by sublegal statute 
right. In addition, this type of interpretation would (probably) lead to the fact that federal 
law would have to be interpreted inconsistently in the individual chamber districts, since 
- as previously described - not all regional medical associations have adopted or will adopt 
the opening clause adopted in the MBO-Ä in their professional regulations. 
 
According to the opinion represented here, it is questionable whether the "mere" offering 
of remote treatment services on a doctor's homepage is already to be regarded as advertis-
ing in the sense of the provision14. However, this is possible in individual cases, depending 			
13  Different view: Julia Braun, Die Zulässigkeit von ärztlichen Fernbehandlungsleistungen nach der Änderung 
des § 7 Abs. 4 MBO-Ä (The admissibility of remote treatment services after the change of § 7 para. 4 MBO-
Ä), 36, MEDR, 563, 566 (2018); Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsauf-
nahme zur aktuellen Entwicklung (Telemedicine and ban of remote treatment – an inventory of the latest 
developments), 36, MEDR, 384, 386 (2018). 
14  According to the Ministry for Social Affairs and Integration of the State of Baden-Württemberg, remote treat-
ment in the context of public services should not be subject to the advertising concept of § 9 HWG, cf. LT B-	
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on the form it takes, due to the broad advertising concept of the law on the advertising of 
therapeutic products 15. Enabling the provision of exclusive remote treatment services 
without mentioning this on the homepage, on the other hand, would be a waste of time. 
Even if the legal literature rightly raises the question of whether "own perception" within 
the meaning of § 9 HWG requires an offline contact purely conceptually16, this will not 
lead to a legally secure solution for the physician. In any case, it has already been decided 
in the case law of higher courts that remote treatment within the meaning of § 9 HWG is 
to be present if the treating person makes a diagnosis or submits treatment proposals 
solely on the basis of written information, information provided by telephone, other me-
dia or third parties at a distance17. Undoubtedly, the online video consultation should also 
be subsumed under this heading. Legislative action is therefore absolutely necessary, not 
least because a violation of § 9 HWG under § 15 para. 1 No. 6 HWG constitutes an admin-
istrative offence, which can be punished with a fine of up to € 50,000.00 (§ 15 para. 3 
HWG). 
 
2. § 48 German Medicines Act (AMG) 
 
Pursuant to § 48 para. 1 sentence 1 AMG, medicinal products intended for human use 
may not be supplied if there has obviously been no direct contact between the doctor and 
the person to whom the medicinal product is prescribed prior to medical treatment18. Ac-
cording to § 48 para. 1 sentence 3 AMG, exceptions may be made in justified exceptional 
cases, in particular if the patient and doctor know each other from a previous direct con-
tact or if the treatment is merely repeated or continued. This provision therefore at least 
opens up the possibility of interpretation to the effect that in the case of remote treatment 
permitted under professional law, there is a justified exception within the meaning of the 
provision. However, this conclusion is by no means mandatory, so that § 48 AMG also 
precludes a meaningful offer of distance treatment services. 
 
			
W printed matter 16/3161 p. 3. This interpretation is, however, at least questionable, since such restriction is 
not included in the wording of § 9 HWG. 
15  Cf. on this topic: Julia Braun, Die Zulässigkeit von ärztlichen Fernbehandlungsleistungen nach der Änderung 
des § 7 Abs. 4 MBO-Ä (The admissibility of remote treatment services after the change of § 7 para. 4 MBO-
Ä), 36, MEDR, 563, 566 (2018). 
16  Cf. Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsaufnahme zur aktuellen Entwick-
lung (Telemedicine and ban of remote treatment – an inventory of the latest developments), 36, MEDR, 384, 386 
(2018). 
17  OLG (Higher Regional Court) Munich, decision dated Aug. 2, 2012 – 29 U 1471/12, MMR 2012, 824. 
18  On the concerns about this provision under European law see Ulrich M. Gassner, Verbot von Online-
Verschreibungen von Medikamenten: Patientenautonomie unter Dauerfeuer (Ban of online-prescriptions of 
medicines: patient autonomy under constant fire), LEGAL TRIBUNE ONLINE, March 31, 2016, 
https://www.lto.de/recht/hintergruende/h/arzneimittel-recht-online-rezept-kontakt-arzt-patient-gesetz-
entwurf-bevormundung/ (last visited Sept. 28, 2018). 
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III. LEGAL LIMITS TO DIGITIZATION: DATA PROTECTION IN THE HEALTH 
SECTOR 
 
The new provisions of data protection law must also be taken into account when assessing 
permissible remote treatment and its limits. Due to the "new" technical possibilities of the 
rapid exchange of large amounts of data, measures must be taken in the interest of the 
persons concerned and the principle of data economy to take account of this change. In 
this respect, the new regulations at least contribute to raising awareness, despite all the 
displeasure. What, then, must doctors pay particular attention to when offering remote 
treatment services relating to data protection? 
 
A. GDPR and BDSG-new 
 
The regulation (EU) 2016/679 on the protection of natural persons with regard to the 
processing of personal data and on the free movement of such data and on the repeal of 
Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as 
"GDPR") entered into force on May24, 2016. In many places, however, it was only per-
ceived shortly before or with its immediate commencement of application in all EU mem-
ber states on May 25, 2018. It is intended to lead to a uniform application of the law and 
to give affected persons more control and transparency, especially in the digital age. The 
innovations go hand in hand with a tightening of the burden of proof on the part of those 
responsible for data processing. The GDPR addresses not only corporations such as 
Google, Facebook and Co., which were the primary target of the legislators in the reform, 
but also small companies, including physicians’ offices, pharmacies and even privately run 
associations. The GDPR does not provide for the possibility of a general exemption for 
smaller units, but it does contain some exceptions, for example with regard to the require-
ment to appoint a data protection officer. 
 
In addition to the introduction of the GDPR, which applies directly in all member states 
and does not require transposition into national law, the Federal Data Protection Act has 
also been amended in Germany and also entered into force on May 25, 2018 (BDSG-neu) 
by adapting some points to the European framework and filling in the reserved opening 
clauses. The criminal provisions are also reserved for the BDSG-new due to the lack of 
regulatory competence of the EU and can be found there in §§ 41 to 43 BDSG-new. 
 
In terms of content, the principles of secure handling of personal data are not entirely 
new. Particularly with regard to sensitive data such as health data, the old BDSG, which 
implemented Directive 95/46/EC, already had high requirements. The increased require-
ments for information and proof obligations can therefore be implemented well by an 
appropriate internal data protection concept. Nevertheless, there are uncertainties in the 
interpretation of the Regulation with regard to individual special questions, which will 
be explained below and which will have to be answered in the near future by binding 
specifications of the European Data Protection Committee, the national data protection 
authorities and decisions of the courts. 
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B. Notions and definitions 
 
First, the question arises as for which information the GDPR is applicable at all. Accord-
ing to Art. 4 No. 1 GDPR, personal data are "any information relating to an identified or 
identifiable natural person ("data subject"); an identifiable natural person is one who can 
be identified directly or indirectly, in particular by reference to an identifier such as a 
name, an identification number, location data, an online identifier or to one or more spe-
cific characteristics which express the physical, physiological, genetic, psychological, eco-
nomic, cultural or social identity of that natural person". This includes in particular in-
formation such as first name and surname, address, telephone number, e-mail address and 
date of birth, which are collected as standard in the medical practice. This is referred to as 
simple personal data. 
 
1. Health data 
 
Particularly sensitive data such as health data are subject to special protection under the 
GDPR. Health data are defined in Art. 4 No. 15 GDPR as such "personal data related to 
the physical or mental health of a natural person, including the provision of health care 
services, which reveal information about his or her health status". According to recital 35 
of the GDPR19, this includes in particular information on past, present or future physical 
and mental health. The information is already personally identifiable if numbers, symbols 
or identifiers assigned to a natural person are used to uniquely identify that natural person 
for health purposes. 
Examples of health data can therefore already be the insurance number, pre-existing con-
ditions, diagnoses (indications), as well as all laboratory results, blood and tissue samples, 
but also disease risks attributable to a natural person. 
 
2. Anonymization and pseudonymization 
 
It should therefore be noted that - in accordance with recital 26 of the GDPR - pseudon-
ymized data also clearly fall within the scope of the GDPR. This also applies if the person 
who receives and processes the pseudonymized data cannot draw conclusions about the 
natural person without consulting further information. Pseudonymization is defined in 
Art. 4 No. 5 GDPR as "the processing of personal data in such manner that it can no 
longer be attributed to a specific person without the use of additional information, pro-
vided that such additional information is kept separately and is subject to technical and 
organizational measures to ensure that the personal data are not attributed to an identi-
fied or identifiable natural person". A classic example is the assignment of an identifica-
tion number to a data set if the "allocation key" still exists. 
 
 			
19  The recitals are binding for the interpretation of the regulation. 	
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Only for anonymous data the GDPR does not apply. However, the terms "anonymous" 
or "anonymization" are not defined. In general, anonymization is presumed when it is no 
longer possible to assign a person to a specific or identifiable natural person20. In this case, 
the allocation key for tracing the identification number back to the corresponding person 
must no longer exist. 
 
The distinction between anonymization and pseudonymization plays an important role 
in the context of remote treatment, especially with regard to the transmission of data. In 
view of the new definition, the transfer of data to medical specialists can no longer be seen 
as anonymization, as it will always be possible to identify the person. In addition, the dif-
ferentiation can become relevant when cooperating with pharmaceutical companies, e.g. 
when creating databases, registers or observational studies. Here, too, anonymization is 
only possible if neither the physician nor the pharmaceutical company can identify the 
individual patient. 
 
It should also be emphasized that any operation relating to personal data constitutes pro-
cessing within the meaning of Art. 4 No. 2 GDPR; even the collection, but also the mere 
deletion, is regarded as processing and no distinction is made between individual pro-
cessing operations. 
 
C. Legal bases for data processing 
 
Furthermore, the fundamental prohibition of data processing without a legal basis, the 
so-called prohibition subject to permission, continues to apply. Corresponding legal bases 
can be found in Art. 6 para. 1 lit. a) to f) GDPR for "simple" personal data, in Art. 9 para. 
2 lit. a) to j) GDPR for special categories of personal data, in particular health data, as well 
as in § 22 BDSG-new. Permission may be granted either by legal basis or by the express 
consent of the data subject. 
 
Although consent is better suited as evidence, the use of a legal basis is likely to be more 
valuable overall - if a legal basis can be substantiated accordingly - as the consent can be 
revoked by the data subject at any time. 
 
To determine the respective legal basis, each processing operation and the purpose of the 
data processing must be considered individually. 
 
1. Medical treatment and health care as a legal basis 
 
Generally, the collection of data by the physician should take place on the basis of the 
treatment contract and thus be permitted in accordance with Art. 9 para. 2 lit. h) GDPR 
in conjunction with § 22 para. 1 b) BDSG-new. A declaration of consent by the patient is 			
20  Cf. PAAL/PAULY/ERNST, DS-GVO KOMMENTAR (GDPR COMMENTARY), Art. 4 Rn. 49 (2nd ed. 2018). 	
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therefore not usually necessary for "normal" treatment. However, due to the principle of 
purpose and data minimization (Art. 5 para. 1 lit. b) and c) GDPR), this only applies to 
the extent that data processing is necessary for the purpose, i.e. for carrying out the treat-
ment, so that the scope of processing is limited to the extent necessary for this purpose21. 
 
But what is the necessary measure for a treatment via electronic communication media - 
e.g. the online video consultation? Is the assessment of necessity to be based on the per-
formance of medical treatment in general, or on the specific form of treatment? 
 
Referring to the treatment contract as a whole, it can be assumed that it is not necessary 
to use additional software to carry out the online video consultation, as the treatment 
contract can also be fulfilled in another way, namely by personal examination in the phy-
sician’s office. The transmission of data by video goes beyond what is necessary, so that 
for the purposes of remote treatment a data protection consent would have to be ob-
tained. Focusing, on the other hand, on the special form of treatment, i.e. remote treat-
ment as such, one would come to the conclusion that no separate consent under data pro-
tection law has to be obtained, because the video consultation hour with the use of addi-
tional communication media is necessary to fulfil the treatment contract in its special 
form. 
 
Also § 7 para. 4 MBO-Ä (new version) does not provide an answer to these questions, but 
only demands in medical regard that "the patient is also informed about the peculiarities 
of the exclusive consultation and treatment via communication media". An additional 
data protection clarification and informed consent is not expressly prescribed in any case 
- unlike, for example, § 40 para. 2a AMG for participation in the clinical trial. 
 
In the direct contact between doctor and patient, the special type of data processing 
should be regarded as necessary according to the view held here. Finally the change of the 
MBO-Ä opens the clearance of the exclusive remote treatment for the physician in the 
context of its therapy choice and under consideration of the medical care to the physician. 
In the same way, within the framework of traditional treatment, he is free to decide on 
the manner and means of treatment in compliance with medical standards. Depending 
on which type of treatment he chooses, the appropriate implementation is necessary for 
the fulfilment of the specific treatment contract, so that no additional data protection 
consent is required in the context of remote treatment. 
 
2. Informed consent for processing of patient health data 
 
However, a direct transfer of personal health data, for example in order to obtain a 
(tele)consultation or in connection with a referral to a specialist - as in the context of con-
ventional treatment - will only be possible with the consent of the patient, cf. also § 73 			
21  EHMANN/SELMAYR/HEBERLEIN, DSGVO KOMMENTAR (GDPR COMMENTARY), Art. 6 Rn. 5 (2nd ed. 
2018). 	
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para. 1b of the German Social Insurance Code (SGB V). It should be emphasized in this 
context that - as described above - pseudonymous data already fall within the scope of the 
GDPR. For this reason, the transmission of an X-ray image or ECG alone - without men-
tioning the patient's name - is already to be regarded as a processing operation22. The pa-
tient's consent must also be obtained for other purposes which go beyond the fulfilment 
of the treatment contract23, e.g. the sending of appointment reminders. Since the transfer 
of data is often part of the treatment, the patient's general consent under data protection 
law will probably have to be obtained in these cases. 
 
D. Further aspects of data protection 
 
1. Rights of the data subject 
 
It is important to note that, independent of the legal basis that permits the processing of 
personal data and health data, the data subject must always be informed in accordance 
with Art. 13 GDPR about the data collection in its concrete form - irrespective of whether 
the patient's consent under data protection law is obtained or not. Depending on the 
technical design, problems may arise with regard to the scope of the information obliga-
tions, for example if other players are involved in addition to the physician (e.g. platform 
operators). At a minimum, the physician must provide information on the identity of the 
person(s) responsible24, the contact details of the data protection officer, the purposes of 
the processing, recipients or categories of recipients, the duration of the processing and 
the rights of the data subjects pursuant to Art. 15 et seq. GDPR to this effect. If the treat-
ment is carried out exclusively via telephone/video telephony, the physician must also in-
form in this way. The reference to a notice in practice would therefore not be sufficient, 
but possibly data protection information on the doctor's website, if he actively refers to it 
during the online video consultation25. An exception to the duty to inform exists accord-
ing to Art. 14 para. 5 lit. d) GDPR if the doctor has received the patient's data from a third 
party (permissibly) and they are subject to professional secrecy. This is the case, for exam-
ple, if the primary care physician forwards the patient data to the specialist because it can 
then be assumed that the primary care doctor has already informed the patient compre-
hensively. 
 			
22  Different according to the former legal status; cf. Wilfried Berg, Telemedizin und Datenschutz (Telemedicine 
and data protection), 8, MEDR, 411, 414 (2004). 
23  Cf. on this topic: Joachim Schütz/Bernd Halbe, Wann die Patienteneinwilligung notwendig ist (When patient 
consent is necessary), ÄRZTEZEITUNG ONLINE (MEDICAL JOURNAL ONLINE), Aug. 24 2018, 
https://www.aerztezeitung.de/praxis_wirtschaft/w_specials/datenschutzverordnung/article/969712/daten-
verarbeitung-wann-patienten-einwilligung-notwendig.html (last visited Sept. 28, 2018). 
24  For joint controlling see below under 4.b. 
25  Also: recommendation of the North Rhine Chamber of Physicians, Die DSGVO in den Praxisalltag integri-
eren (Integrating GDPR into the physician’s routine), RHEINISCHES ÄRZTEBLATT (RHENISH MEDICAL 
JOURNAL), 8, 12 et seq (2018). 	
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In addition, the requirements of Art. 9 para. 3 GDPR must be fulfilled. Accordingly, pro-
cessing is only permissible if it is carried out "by specialist personnel or under their respon-
sibility" and if this specialist personnel or the person responsible for data processing is 
subject to a statutory professional secret or other confidentiality obligation26. This shall 
include appropriate measures to safeguard the interests of the data subject and data secu-
rity in general27. 
 
Furthermore, it must be ensured that the data subject can exercise his or her right to in-
formation (Art. 15 GDPR) and, if applicable, data portability (Art. 20 GDPR) without 
any problems. The latter means that the patient can request a copy of his patient file. 
However, it only exists if the processing is based on consent or a contract and is carried 
out using automated procedures. In the case of remote treatment, this means that the pa-
tient has no right to data transferability if the data processing is based - as described above 
- on the treatment contract as legal basis, since the legal basis of the health care and the 
treatment contract from Art. 9 para. 2 lit. h) GDPR is not mentioned in the concluding 
enumeration28 of Art. 20 para. 1 a) GDPR29. The right of the patient to inspect the patient 
file according to § 630g of the German Civil Code (BGB) remains unaffected by this. In 
contrast to the right under Art. 20 GDPR, the physician is not given a deadline to react 
and the patient must bear the costs incurred himself. 
 
Even if a third party is involved as platform operator, this should not lead to a different 
result: A contract within the meaning of Art. 6 para. 1 lit. b) GDPR would – if at all – be 
concluded between platform operator and physician - but not between platform operator 
and patient30. Apart from hat, however, only the processing of "simple" personal data by 
the platform operator would be permitted, which would not be sufficient for the desired 
purposes. 
 
2. Joint controlling/Commissioned data processing 
 
Since the GDPR came into force, there have also been new responsibilities for the involve-
ment of several actors in connection with data processing. Art. 4 No. 7 GDPR defines the 			
26  Cf.EHMANN/SELMAYR/SCHIFF, DSGVO KOMMENTAR (GDPR COMMENTARY), Art. 9 Rn. 61 (2nd ed. 2018). 
27  So called technical and organizational measures (TOMs) such as access restrictions, password protection, en-
cryption and ensuring the integrity and availability of systems, etc., cf. Art. 24 para. 1 GDPR, § 22 para. 2 
BDSG-new. 
28  Cf. recital 68; PAAL/PAULY/PAAL, DS-GVO KOMMENTAR (GDPR COMMENTARY), Art. 20 Rn. 18 (2nd ed. 
2018). 
29  In the result also: Andreas Wolf, Die Fernbehandlung nach dem 121. Deutschen Ärztetag im Lichte der 
DSGVO (Remote treatment after the 121st German Medical Association in the light of the GDPR), 4, GUP, 
129 et seq (2018). 
30  Different view: Andreas Wolf, Die Fernbehandlung nach dem 121. Deutschen Ärztetag im Lichte der DSGVO 
(Remote treatment after the 121st German Medical Association in the light of the GDPR), 4, GUP, 129 et seq 
(2018). 	
		 COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
ANNA KRISTINA KUHN & MARIE-ISABEL HEINZ   |  DIGITIZATION IN THE HEALTH SECTOR IN THE TRADE-OFF BETWEEN 
TECH-NICAL AND LEGISLATIVE POSSIBILITIES AND LEGAL LIMITS ACCORDING TO GERMAN LAW 
 
PAGE  49 
person responsible as the person who alone or jointly with others differentiates between 
the purposes and means of data processing. Accordingly, anyone who collects, stores, 
transmits, etc. data for himself is responsible. Responsible person in the sense of the 
GDPR31. In contrast, the processor is, according to Art. 4 No. 8 GDPR, a person or body 
who processes personal data on behalf of the data controller. The delimitation is im-
portant because the responsible person and the processor have different obligations32 and 
a corresponding agreement must be reached on the distribution of responsibilities in ac-
cordance with Art. 26 or Art. 28 GDPR.  
 
Due to the contractual and professional duties of a physician to document patient data 
and to archive it beyond the treatment33, the physician defines the processing purposes at 
least to this effect and is therefore generally to be regarded as the person responsible. The 
specialist to whom the referral is made by the family doctor also does not act as processor 
on behalf of the primary physician34, since an independent legal relationship is established 
with the patient and he does not act on his behalf35. Cooperation between physicians and 
pharmaceutical companies - not only within the framework of clinical trials36 - will also 
regularly be a joint responsibility, since in some areas decisions are made on data pro-
cessing and corresponding internal regulations are required.  
 
In the context of remote treatment, it is conceivable, depending on the technical imple-
mentation, that the physician may use one or more service providers who, in accordance 
with their dependence on the physician's mandate or their own influence on data pro-
cessing, are to be classified as contract processors or joint responsible parties. 
 
3. Data protection officer 
 
In addition, the appointment of a data protection officer pursuant to Art. 37 GDPR will 
be necessary in practices offering remote treatment. Although the core activity of a medi-
cal practice mentioned in Art. 37 para. 1 lit. c) GDPR is not usually seen as an extensive 			
31  PAAL/PAULY/ERNST, DS-GVO KOMMENTAR (GDPR COMMENTARY), Art. 4 Rn. 55 (2nd ed. 2018). 
32  At the same time, the obligations of commissioned data processors have increased and an independent liability 
has been established. 
33  Cf. § 630 f para. 3 BGB, § 28 RöV (X-Ray Regulation). 
34  According to the statement of the Data Protection Officer of North-Rhine Westphalia, which is no longer 
available, cf. the resolution of the Concerted Action of the Professional Associations at the German National 
Association of Statutory Health Insurance Physicians, June 22, 2018, http://www.kbv.de/html/35530.php (last 
visited Sept. 28, 2018). 
35  Already: BGH (Federal Supreme Court), decision dated Jan. 14, 2010 – III ZR 188/09, NJW 2010, 1200; BGH, 
decision dated Jan. 14, 2010 – III ZR 173/09, NJW 2010, 1203. 
36  Cf. Short paper of the Data Protection Conference on Joint controlling, March 19, 2018, 
https://www.ldi.nrw.de/mainmenu_Aktuelles/submenu_EU-Datenschutzreform/Inhalt/EU-Datenschutz-
reform/KP_16_GemeinsameVerantwortliche.pdf (last visited Sept. 29, 2018). 	
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processing of personal data37, it is subject to the duty to assess the impact of data protec-
tion due to the "use of new technologies" pursuant to § 38 para. 1 sentence 2 BDSG-new 
in conjunction with Art. 37 para. 1 GDPR, so that even smaller practices with less than 
ten employees must appoint a data protection officer when offering remote treatment. In 
addition, a list of processing activities in accordance with Art. 30 GDPR must be main-
tained in which the steps to be taken in connection with remote treatment must be listed 
as individual processing steps. 
 
Finally, what are the consequences of the GDPR for breaches of data protection provi-
sions? On the one hand, the framework for the imposition of fines has been drastically 
increased and can now amount to up to EUR 20 million or 4% of the annual turnover in 
the case of serious infringements, for example of consent requirements or the rights of the 
data subject pursuant to Art. 83 para. 5 GDPR. On the other hand, pursuant to Art. 82 
para. 1 GDPR, the data subject has a claim for damages against the data controller and the 
processor if he or she succeeds in proving material or immaterial damage resulting from a 
breach of data protection. 
IV. CONCLUSION 
 
The amendment to § 7 para. 4 MBO-Ä (new version) is a first important step towards 
enabling exclusive remote treatment, which is becoming increasingly important in the 
course of digitization. Fortunately, it has now been recognized that the current attempt 
to close off the German healthcare market from remote treatment cannot be the future. 
The restraint of the medical profession in this regard can only be countered, however, if 
more legal clarity is created regarding the interpretation of the new professional regula-
tions and regarding the possible consequences of the impending fragmentation of profes-
sional law with regard to the prohibition of remote treatment. In addition, legislative ac-
tion is absolutely necessary, as the currently applicable statutory provisions blatantly 
stand in the way of a meaningful offer of distance treatment services. In addition to the 
professional limits, the physician in charge must also take into account the new data pro-
tection regulations, which will entail a number of organizational hurdles. Against the 
background of stricter accountability obligations and monetary liability risks, compliance 
plays an increasingly important role in this context. 
 
			
37  Different view: Chamber of Physicians of the State of Hesse, which advises to appoint a data protection officer 
in health care institutions with less than ten employees at least for a transitional period of two years, cf. 
Handout on Appointment of DPO in the view of the Chamber of Physicians of the State of Hesse, 
https://www.laekh.de/images/Aerzte/Neues_Datenschutzrecht/Bestellung_eines_Datenschutzbeauftrag-
ten.pdf (last visited Sept. 29, 2018). 
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I. THE DIGITAL DATA WORLD IS BECOMING THE CORE OF MEDICINE 
AND HEALTHCARE 
 
Who lives outside the GAMFANNAT economy (Google2, Apple3, Microsoft4, Face-
book5, Amazon6, Netflix7, Alibaba8, Tencent9)? An increasing market capitalization of 
approximately $5 trillion (July 2018) – a multiple of the market value of all German DAX 
30 companies together – and an even deeper connection of services and products with our 
increasingly digitally organized and experienced life clearly show that large parts of the 
global consumer society today and even more tomorrow and the day after tomorrow will 
become data-driven spheres. It is easy to imagine a world without fossil fuel-powered au-
tomobiles – but with flying autonomous vehicles, a bit harder without cell phones - and 
with brain implants - but a world without data in the sense of their intensive generation 
and usage, and practically in all areas of life – it seems to be hardly tangible (unless as a 
conscious and fairly complete renunciation of technology).  
 
The development of data-driven activities as a whole is increasingly ethically questioned. 
In Germany, the Data Ethics Commission10 has recently been created within the Federal 
Ministry of Interior, Building and Community, and in England the Data Ethics Frame-
work11 of the Department for Digital, Culture, Media and Sport. Today, it is equally un-			
2  For insights into strategies and business cases for listed companies, investor relation platforms are helpful 
(alongside with (good) capital market research); Alphabet Investor Relations, https://abc.xyz/investor/ (last 
visited Oct. 20, 2018, 09:21 AM). 
3  Apple Investor Relations, https://investor.apple.com/investor-relations/default.aspx (last visited Oct. 20, 
2018, 09:11 AM). 
4  Microsoft Investor Relations, https://www.microsoft.com/en-us/investor (last visited Oct. 20, 2018, 09:10 
AM). 
5  Facebook Investor Relations, https://investor.fb.com/home/default.aspx (last visited Oct. 20, 2018, 09:04 
AM). 
6  Amazon Investor Relations, https://ir.aboutamazon.com/ (last visited Oct. 20, 2018, 09:16 AM). 
7  Netflix Investors, https://ir.netflix.com/ir-overview/profile/default.aspx (last visited Oct. 20, 2018, 09:23 
AM). 
8  Alibaba Group, https://www.alibabagroup.com/en/ir/home (last visited Oct. 20, 2018, 09:25 AM). 
9  Tencent Corporate Governance, http://www.tencent.com/en-us/investor.html (last visited Oct. 20, 2018, 
09:31 AM). 
10  Datenethikkommission, Bundesministerium des Innern, für Bau und Heimat (Data Ethics Commission, Fed-
eral Ministry of the Interior, for Building and Community) https://www.bmi.bund.de/DE/themen/it-und-
digitalpolitik/datenethikkommission/datenethikkommission-node.html (last visited Oct. 20, 2018, 09:37 
AM). 
11  Guidance – Data Ethics Framework, Department for Digital, Culture, Media & Sport (updated Aug. 30, 2018), 
https://www.gov.uk/government/publications/data-ethics-framework/data-ethics-framework (last visited 
Oct. 20, 2018, 09:42 AM). 	
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imaginable not using the digital advances in medicine – which are certainly critical in eth-
ical terms, yet impressive, especially the data-driven ones – for positive precaution, diag-
nosis, healing and aftercare opportunities for patients and healthy people. From AI in 
radiology to precision medicine in oncology, people want to be, become, and stay healthy. 
Here a peculiar tension erupts. 
 
In the GAMFANNAT world, considerably more people are using the services offered 
than would be expected in view of the level of trust that users have in their data usage – 
apart from the fact that hardly anyone, for example, really works through, understands or 
can decipher privacy statements. Transparency as a condition of the opportunity for fair 
consent looks different. To put it clearly: The GAMFANNAT Grandpa should not be 
sitting next to Lehman Granny. Nor is it to be expected that, in the end, patients will not 
give priority to the medical benefit of their data because of concerns about a "patient 
credit bureau" – even if the treatment contexts are hardly accessible to the individual pa-
tient. Convenience has always limited data protection requirements in real terms, and data 
protection should not be a luxury for the healthy. In addition, the GAMFANNAT play-
ers are already today – recognizable openly or only in contours – increasingly active in the 
medical and healthcare market and game changers.12 
 
So what data-related opportunities and risks arise for patients from a business perspec-
tive? How can patients not only be masters of their data, but use data business cases for 
themselves? What is the value of their medical and health-related data? Which commer-
cial, social or individual medical use of personal data makes sense and is as safe as it can be 
safe in the digital realm? 
II. ECONOMICALLY, DATA IS NEITHER OIL NOR CURRENCY – BUT NEV-
ERTHELESS THE CENTRAL FUTURE EXCHANGE UNIT FOR PATIENTS 
 
Economically, oil is private property with exclusive ownership. My oil is my oil and only 
I can use it, nobody else. And when it's used up, it's gone. And I can only use one liter of 			
12  Google: Recently expansion into healthcare, strong strategic focus (Google in Health, GOOGLE 
https://www.google.com/intl/en_us/health/about/ (last visited Oct. 20, 2018, 10:01 AM)); Apple: Recently 
Apple Watch 4 has been classified as an FDA class 2 medical device and launched the project of medical clinics 
for employees, strong strategic focus (Healthcare- The future of healthcare is in your hands, APPLE, 
https://www.apple.com/healthcare/ (last visited Oct. 20, 2018, 10:12 AM)); Microsoft: Recently more azure 
services for next gen medical data (e.g. Genomics), strong strategic focus (Health - Learn more about what 
Microsoft is doing in Health, MICROSOFT, https://www.microsoft.com/en-us/enterprise/health (last visited 
Oct. 20, 2018); Facebook: Recently data sharing agreement with hospitals, growing strategic focus (Christina 
Farr, Facebook sent a doctor on a secret mission to ask hospitals to share patient data, CNBC (Apr. 5, 2018) 
https://www.cnbc.com/2018/04/05/facebook-building-8-explored-data-sharing-agreement-with-hospi-
tals.html (last visited Oct. 20, 2018, 10:17 AM)); Amazon: Recently partnering with JPMorgan Chase and Berk-
shire Hathaway, yet unclear goal, probably using the sales and payment power of Amazon for healthcare, phar-
macy or insurance to increase efficiency in healthcare (Zachary Tracer, Amazon-Berkshire-JPMorgan Health 
Venture Takes Aim at Middlemen, BLOOMBERG (Jun. 24, 2018) https://www.bloomberg.com/news/arti-
cles/2018-06-24/amazon-berkshire-jpmorgan-health-venture-takes-aim-at-middlemen (last visited Oct. 20, 
2018, 10:22 AM)); also Netflix, Alibaba, Tencent are active, also Uber et al. 
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oil to the extent of one liter of oil. If I mix 1,000 liters of oil, it won’t become "super oil". 
In economic terms, data have a completely different nature. I can share my data with mul-
tiple users, so they are not rivals, and when many different pieces of data come together, 
they create network effects that can in part lead to significant benefit increases. In addi-
tion, data can be copied virtually unlimitedly, does not wear out, can be transferred, and 
can be handled through access, use, and change, and distinguished into private club goods 
or public data assets (e.g. weather data). And you can do amazing mathematics with it: 
statistics is the new basic subject for understanding the data economy.  
 
My personalized medical data may only have limited economic value for me – which may 
be existential – but economically cannot be increased arbitrarily. However, for a com-
pany, various data such as my personalized but also impersonalized data (anonymized, 
pseudonymized, or purely machine-generated) can, when aggregated, lead to completely 
new insights and offers, and in the end even to innovative value added – especially in 
modern data medicine, such effects are currently on the agenda, and therefore, for exam-
ple, for the pharmaceutical industry, of great interest.  
 
The emancipation of correlation versus causality does not take place in strict scientific 
theory, but in the pragmatic world of business models13 – even with seriously anonymized 
data, cross-referencing and correspondingly smart data analysis models can often at least 
compensate for the information about the person that has been legally deleted, provided 
that those data are cleverly combined with other data (e.g. data from search engines or 
fitness devices) apart from that it is known that 87 percent of the US population can be 
re-identified by the combination of zip code, gender and date of birth.14 Precisely because 
my data does not generally represent a significant value for me, there was – and is – a 
tendency to pass it quite relaxed to the companies in exchange for services and products. 
That's just how it is as a consumer: “If you are not paying for it, you're not the customer; 
you're the product being sold”.15 
 
In the end, to a large extent, the enormous market value of the corresponding data-driven 
companies is explained. Because they do not really share the cake. With a view to patients, 
this trend slowly begins to gain contours in the medical and healthcare sector. Strictly 
speaking, the medical data of patients is not a currency for patients themselves, because 
they are not a constant reference value, but depend essentially on their context. However, 			
13  To be very clear here: „In today’s world, there is a growing tendency to trust personal beliefs, superstitions, 
and pseudoscience more than scientific evidence.“, Helena Matute, Fernando Blanco, Ion Yarritu, Marcos 
Diaz-Lago, Miguel A. Vadillo & Itxaso Barberia, Illusions of Causality: How They Bias Our Everyday Think-
ing and How They Could be Reduced, 6 FRONTIERS IN PSYCHOLOGY, 888 (2015) – That is an unacceptable 
tendency. We should not let Bias become acceptable. It might be true, that rich people have big feet – if I hit 
the jackpot my feet will not grow - but that does not excuse to hit the other extreme: Of course correlation-
based business models can make sense and produce value for customers. 
14  Latanya Sweeney, k-anonymity: a model for protecting privacy, 10(5) INTERNATIONAL JOURNAL ON UNCER-
TAINTY, FUZZINESS AND KNOWLEDGE-BASED SYSTEMS, 557-570 (2002). 
15  Andrew Lewis via Twitter, Sept. 13, 2010, available at: https://twitter.com/andlewis?lang=en (last visited Aug. 
10, 2018, 03:25 PM). 
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data can replace financial transactions via their specific value – and yet, no oil, no cur-
rency, but an economic value that should be repaid. 
III. BUSINESS MODELS FOR THE USE OF MEDICAL DATA AND IDEAS FOR 
DETERMINING THE VALUE OF DATA ARE DIVERSE AND RARELY REC-
OGNIZABLE TODAY 
 
Which business models in the medical and healthcare industry use data and how is this 
money earned? This very simple-sounding question says it all. In principle, data can be 
traded or used directly (or as in the case of open-data provided without consideration, or 
data sharing). The GAMFANNAT economy usually does the latter and thus comes to 
steadily richer and deeper user experiences and increased, individual benefit, leading to a 
corresponding willingness to pay and, above all, loyalty – and last but not least, to com-
petitive advantages. The algorithms of the companies are ultimately unregulated and in 
large parts even for an insider a black box – which makes the exact analysis of the value-
added context not easier, as well as a social assessment (think of the potential for discrim-
ination, currently the Berlin initiative d2116 is taking corresponding first steps with the ex-
pert group "Algorithms Monitoring"). What is still emerging in medicine as personalized 
medicine, for example, is for consumers of media an everyday experience (certainly media 
are far less complex and consequential). Today we see no “MediFy”, but Spotify 17 
 
When it comes to trading data (as practiced by IQVIA18, for example), transparency is less 
visible. Who really knows how their health insurance provider does the ultimately decisive 
risk assessment? Which data were used? The fact that you can no longer digitally live with-
out advertising and this advertising is personalized on a data-driven basis, may cost some 
nerves and evoke countermeasures, such as paying for less advertising; others enjoy hyper-
personalized content – but ultimately, it's a comparatively less critical data usage. With 
Patient Data Selling you will want to look more closely – and have to. The opt-out must 
always be possible for the patient, but today it is not. Just say “No” if you do not want to 
be part of the game (as long as it is doable for the average person). And a solution such as 
privacy-enhancing tools, which are available for online offers, for example, are far from 
available for medical data and records. The data system of the medical and health industry 
has a breathtaking opacity. 
 
Good providers of data services will ensure transparency and participation, and legally 			
16  See: Netzwerk für die Digitale Gesellschaft (Network for the Digital Society), D21 https://initiatived21.de/ 
(last visited Oct. 20, 2018, 01:01 PM). 
17  Spotify is partnering with DTC-Company Ancestry to combine playlists with DNA (If you could listen to your 
DNA, what would it sound like?, ANCESTRY, https://www.ancestry.com/cs/spotify (last visited Oct. 20, 2018, 
01:15 PM) – sounds wired but entertainment is a valid way to create awareness and to start the empowerment, 
just think of gamefication as a means to create smart learning effects. 
18  IQVIA, https://www.iqvia.com/ (last visited Oct. 20, 2018, 01:19 PM), founded 1982 (!) as Quintiles IMS 
Holdings. 	
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offered to patients integrating them economically (and of course the doctors, who will 
soon be seeing new business models in the house, new risks but also new opportunities; 
no AI will ever replace a good heart (until we do not see an AI as an Existence in the full 
ethical sense) and doctors are always the natural intelligence needed, think of the actual 
critical discussion of Watson19 (IBM)). And pay attention to the data quality: Statistical 
modeling is only suitable for intervention in medicine, if it has at least objectivity, relia-
bility and validity with regard to the actual data used and the corresponding analysis 
methods. With good data, medical systems can be trained and multiple variables can clev-
erly be linked to newly empirically demonstrable correlations, which in turn may suggest 
prevention or therapy. Unfortunately, even with data success, neither the corresponding 
model can be verified nor a causality be proven. Statistics make more or less meaningful 
predictions depending on the sample size. But that's just what makes new hypotheses pos-
sible. And with the exponentially growing flood of information in the medical sector, it's 
difficult to avoid big data and AI (& Co.). In this sense, in my opinion, patients in the 
medical and healthcare sector want to deal with their data more sensitively than in previ-
ously common consumer areas – and hopefully do it well-informed – and in the end want 
to use the statistically usable or even personal data generated value. 
 
On the other hand, what speaks in principal against patients paying in a transparent and 
well-structured manner, for example, special medical services in a smart hospital with their 
data? Self-pay may also be achievable for less wealthy patients. What speaks against a pa-
tient selling or licensing their genetic data for legal and legitimate and transparent pur-
poses? In the upcoming DNA marketplace, the DNA “donors” should get an economic 
participation and become “business partners”; smaller companies such as EncrypGen20 or 
Nebula Genomics21 look for appropriate solutions, and often-key technologies such as 
Blockchain play a crucial role. Consequently, questions about the taxation of data will 
also have to play a bigger role in the future. And, of course, security and economic value 
issues – hacker attacks from outside and criminal energy within medical institutions – are 
likely to increase as the incentive potentially increases. 
 
Patients may not have a clear understanding of what their data is really worth, and most 
of them might not care about the business models at this stage without recognizable par-
ticipation (in a democratic sense). Companies in the medical and healthcare industry have 
a decisive advantage here, not least because the value of data constantly changes with the 
context of (today often unclear, but tomorrow…) business models. Of course, companies 
are often denied the final clarity on digital business models in the smart healthcare world. 
In the end, it will be crucial whether patients are adequately involved in certainly-not- 			
19  Annie Palmer, IBM's Watson AI suggested 'often inaccurate' and 'unsafe' treatment recommendations for can-
cer patients, internal documents show, DAILY MAIL ONLINE, https://www.dailymail.co.uk/sciencetech/arti-
cle-6001141/IBMs-Watson-suggested-inaccurate-unsafe-treatment-recommendations-cancer-patients.html 
(last visited Oct. 20, 2018, 01:28 PM). 
20  EncrypGen, https://encrypgen.com/ (last visited Oct. 20, 2018, 01:33 PM). 
21  Nebula – Genomics, https://www.nebula.org/ (last visited Oct. 20, 2018, 01:34 PM). 	
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marginal welfare gains. Enlightenment is likely to be necessary not only in legal but also 
in economic terms, otherwise consent declarations remain notoriously ineffective and 
economically not necessarily positive for the client or patient, because the data-collecting 
company determines what data it collects for what. But alternatives are also discussed, for 
instance, personal information management systems (PIMS22). Also important are Smart 
Communities to engage Patients in Dialogues about their data commercialization enter-
prise among themselves and with medical and other experts.  
 
Not least so that the patients not only – as usual in the data economy from the customer's 
point of view – look for short-term benefits such as discounts or the like, but also take 
long-term positive effects into focus. This decision-making need not necessarily leads to 
the decision between added value and the protection of data but can combine both ele-
ments. It will not necessarily be about life-changing business when patients use their data 
or parts of their data economically. But then they are in the game, sitting at the table, and 
they also should sit there, if, in the end, it comes not through advertising but e.g. via in-
surance model-funded data platforms. At the end of the day, the patients themselves can 
increase the price and promote transparency by treating their data with the utmost care, 
which will be essential for an adequate position of providers (patients) towards buyers 
(companies). And today it is not foreseeable whether there will be minimal value added, 
exchangeable, or even a greater value added in the individual economic exploitation of 
individual, personalized or impersonalized data. A third way to do this would be to point 
out the current, ultimately unquestioning availability of data and self-marketing of the 
individual, which is likely to lead to lower prices through asymmetry. 
 
Unlike other consumer data, medical data is absolutely necessary for factual medical care, 
but for the healthy some medical data are theoretically economically usable even without 
specific treatment, and not even prevention. Finally, the entire life as a prevention and 
data event is newly articulated in the quantified self. It will probably result in a holistic 
path connecting EMR Data, wearables, and B2C-driven genetic data. A conceivable im-
pact can be the connection between pay and data exploitation, as it is known and prac-
ticed in the media industry23. The licensing of intangible assets answers the question as to 
which data, where, when, for how long, to whom and for what purpose and consideration 
are put into use.24 Companies like to talk about "data ecosystems" as Terminus Technicus 
instead of "trade". Platforms to value and trade/licence C2B and maybe even C2C could 			
22  Personal Information Management System, European Data Protection Supervisor, https://edps.eu-
ropa.eu/data-protection/our-work/subjects/personal-information-management-system_en (last visited Oct. 
20, 2018, 01:37 PM). 
23  It is expectable that disruptive media businesses – e.g. in video gaming, music, film (content) and advertising 
(which see a digitalization-driven convergence tendency in their own value chains) – will cooperate with health 
data businesses (see footnote 6 for a recent example). One reason besides value creation might be located in the 
inner logic of these data-business. 
24  Wolfgang Kerber, Digital Markets, Data, and Privacy: Competition Law, Consumer Law, and Data Protec-
tion, 11 (11) JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 856–866 (2016). 	
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be an instrument – but always and only if Patients are educated to handle their medical 
data, which is for example for sure one of the challenges von DTC (direct to consumer) 
genomic businesses (23andme25 etc.) because People are confronted with information 
(might it not be a diagnosis) which they maybe are not able to handle on their own with-
out further professional advice, e.g. by a doctor.  
In practice, such basically legal issues are not really resolved. In the case of personal data, 
the term "property" – or at least property-like entitlements – may be used, and in the case 
of non-personal data, it may be called a copyright aspect. Since there are many mergers of 
data forms that are likely to increase in the Internet of Things era, even this distinction 
with property reference may be difficult in practice, and thus the likelihood of lower 
transaction costs for personal data and its markets. The lawyers will get a lot to do. 
 
If it is ethically correct and therefore legally required in a constitutional state to focus on 
the patient's benefit, and also economically attractive – albeit a little weird that the patient 
has to become a customer in order to be a human being with dignity in the health business 
– then the consistent empowerment26 of patients to handle their own data is essential. 
And this does not in the least include the benefit that these can provide – only for the 
individual patient medically, but also financially, or, for example, by means of data dona-
tion in research, potentially for society as a whole or in cooperative models (eg Health-
bank27 in Switzerland). For this, a social consensus must be worked out that supports this 
form of economic participation. In addition, the lack of factual interoperability of exist-
ing patient records is a major obstacle for convincing implementation – and a significant 
costly one as well. There are initiatives such as MyData28 from Finland, which generally 
demand a "human-centered personal data management" for data, and with the concept of 
the "Self-Sovereign Identity Systems" the final idea of the autonomy of users finds its way 
into the debate. New companies like Longenesis29 also build on similar approaches. 
 
			
25  23andMe, https://www.23andme.com/en-int/ (last visited Oct. 20, 2018, 01:56 PM). 
26  Approaches such as gamification might be useful here, just as the inclusion of relevant multipliers in the edu-
cational realm, e.g. schools for continuing non-credit education (so-called „Volkshochschulen“ in Germany). 
In my opinion the issue of health data has to be addressed from kindergarten to higher education and for every 
target group – think of STEM Initiatives to foster tec talents for example.  
27  Health Bank, https://www.healthbank.coop/ (last visited Oct. 20, 2018, 02:52 PM). 
28  Mydata Finland, https://mydata.org/finland/ (last visited Oct. 20, 2018, 02:21 PM). 
29  Longenesis, http://longenesis.com/ (last visited Oct. 20, 2018, 02:16 PM). 
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Figure 1: The centrality of the patient in the commerce of digital healthcare 
 
 
IV. THE GDPR POTENTIALLY DRIVES THE INDIVIDUAL DATA BUSINESS IN 
MEDICINE 
 
In my opinion, the General Data Protection Regulation (GDPR)30 tries to manage the 
balancing act between data protectionism and innovation bondage in favor of a reasona-
ble middle-of-the-range solution. It can – despite all certainly not unjustified criticism in 
detail – become the gold standard (for now) to make personal data with privacy and data 
portability a valuable asset in a seller's market. Businesses, as well as other public-sector 
institutions, for example, who deal with impersonalized data and, most importantly, per-
sonal data of patients, are highly demanded to ensure the maximum possible security of 
this data from misuse. Since like I mentioned true impersonalized data is not easy to grant, 
this form of data although not covered by the GDPR should be considered data protec-
tion relevant when we talk about patient data. 
  
Additionally, it is a good initiative of the GDPR to put the consent clearly in the center. 
It is about protection people, not protecting data.31 In the end, patients will have to learn 			
30  Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection 
of natural persons with regard to the processing of personal data and on the free movement of such data, and 
repealing Directive 95/46/EC (General Data Protection Regulation), EUR-Lex, https://eur-lex.europa.eu/le-
gal-content/EN/TXT/?uri=CELEX:02016R0679-20160504 (last visited Oct. 20, 2018, 04:26 PM). 
31  The GDPR, in fact, is counterproductive when it comes down to the real business life. A little less complex, 
rigid and punitive might have been more suitable. In Germany things are, of course, even more complex. 18 
independent data Protection authorities exist in Germany. Sometimes simplicity and clarity might be a better 	
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to responsibly handle the most valuable data they have – their medical data – and to read 
the privacy policy. The "fine print" re-enters the consciousness – and that's a good thing. 
In addition, the much-cited informational self-determination is no guarantee of absolute 
power of the individual over "their" data – because also the protection of privacy takes 
place in a social context. And yet there remains the problem that the GDPR does not 
directly address the involvement of consumers in the economic exploitation of their data. 
It is easy to understand, however, that consumers want more than data protection as soon 
as the economic opportunities in data markets become clearer to them.32 At the end of the 
day, it should be similar for patients – not just because of private return perspectives but 
also to foster their healthcare outcomes. Which on the other hand might also increase 
their motivation e.g. to share their data with research organizations and become a proud 
data donor. Precision medicine for everyone needs so many institutional barriers to over-
come – Patients as smart customers can make it happen.  
 
No sensible person can object to better medicine; however, care must be taken to ensure 
that there are no distorting data monopolies and non-transparent business models that in 
the end only really benefit a few players. If a legal, legitimate and efficient business is to 
emerge, it must properly engage patients as customers and data providers in the value 
chain. The centrality of the patient in the commerce of digital healthcare is crucial – also 
from my point of view for a holistic patient experience - even though it may be very com-
plex and difficult, it is not impossible. 
			
way to protect people and business as well as to help to avoid the misuse of their data than the current confus-
ing legal framework. An international comparison of approaches is possible, e.g. the Hong Kong Personal Data 
(Privacy) Ordinance, the Australian Privacy Act, the Singapore Personal Data Protection Act etc. - for a good 
global overview check: Data protection around the world, DNIL, https://www.cnil.fr/en/data-protection-
around-the-world (last visited Oct. 20, 2018, 04:31 PM). 
32  Sarah Spiekermann & Jana Korunovska, Towards a value theory for personal data, 32 (1) JOURNAL OF INFOR-
MATION TECHNOLOGY, 62-84 (2017). 
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ABSTRACT 
Compliance, defined as the obligation to follow particular rules1 at the institutional level, 
can hardly be considered while disregarding individual actors: after all, it depends on the 
value orientation of their attitudes and actions.2 Compliance with the law forms the basis 
for the actions of all companies, including universities. In Switzerland, most universities 
have no explicit compliance guides, but they often do have other guidelines that allow mak-
ing statements about the identity of the institution. The Zurich University of Applied Sci-
ences (ZHAW) has made social integration a priority for 2017/2018. Within the scope of 
this priority area, 13 research projects were funded; in this case, the subtopic was “work, 
diversity, living space and social security”. In addition, the Department of Social Work 
provided ad hoc support for smaller projects that illustrate the aspect of social integration. 
Thus, this institution does not only set guidelines, but also actively promotes them. However, 
the question remains open as to whether the individual actors act and think in accordance 
with the guidelines of their institution. As part of a research project on value orientation3 			
1  AMITAI ETZIONI, A COMPARATIVE ANALYSIS OF COMPLEX ORGANIZATIONS: ON POWER, INVOLVE-
MENT, AND THEIR CORRELATES 33 et seq. (1961). 
2  MILTON ROCKEACH, THE NATURE OF HUMAN VALUES (1973). 
3  Project Nr. 162380 of the Swiss National Fonds, accessible at: http://p3.snf.ch/Project-162380 (last visited Apr. 
26, 2018, 01:30 PM). 
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funded by the Swiss National Science Foundation, ZHAW employees were selected as a 
reference group and asked about their value orientation. The social factor being a crucial 
focal point at institutions of higher education, the survey was intended to show both the 
heterogeneity of the group and its common ground: the values shared by all the respondent 
members that are instrumental in guiding their actions. The precise manifestation of the 
respondents’ social values was also of interest. 
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I. COMPLIANCE AND VALUES: THE KNOWLEDGE BASE 
 
Compliance, in a general sense of following certain rules, may occur in any social context 
in which people interact with each other.4 
In business, compliance is understood to mean strategies that pursue the conformity to 
laws, as wells as regulations in the broadest sense.5 In the following, we will refer to eco-
nomics and organizational sociology; while we are aware that universities are not compa-
nies in the usual sense, they – at least the universities of applied sciences in Switzerland – 
are held economically accountable, being partly financed by providing services and at-
tracting research funds. In this area, the observance of rules (even unwritten ones) is par-
ticularly important, forming as it does good scientific practice. If we take a closer look at 
the definitions of compliance from the perspective of economics, we see that in Roth’s6 
understanding, for instance, the basis of compliance is a legal duty of companies to ensure 
that no violations of the law occur; however, the objective goes beyond this duty: compli-
ance presumes not only that companies, i.e. their managers and all employees observe the 
laws but also that ethical standards shape the company’s relationship to various stake-
holder groups. In relation to economics, organizational sociology also deals with the issues 
of legal compliance in companies. Key issues in this context are compliance with rules as 
well as moral and ethical guidelines. Moral action is dictated by value orientations7; ethics 
are presently defined as principles that assume value-orientation as a norm for human 
action.8 
 
In some cases, it is questionable whether social values agree or can be harmonized with 
organizational values, and how these possibly diverging values influence the actors. We 
may also ask whether value orientations may influence organizational goals and values. In 
economic processes, financial gains can often be more important than social values, and 
the pursuit of economic goals can lead enterprises into conflict with its declared social 
orientation.9 An organisation’s guidelines might also conflict with the individual values 
of its members. A crucial aspect of this conflict is information asymmetry: the official val-
ues of organisations are usually known; those of their members usually remain undis-
closed. In the following, examples of compliance at Swiss universities will be discussed to 
shed light on the individual reflexive values of employees. 			
4  MITAI ETZIONI, A COMPARATIVE ANALYSIS OF COMPLEX ORGANIZATIONS: ON POWER, INVOLVEMENT, 
AND THEIR CORRELATES 3 et seq. (1961). 
5  MONIKA ROTH, COMPLIANCE – VORAUSSETZUNG FÜR NACHHALTIGE UNTERNEHMENSFÜHRUNG. EIN 
BRANCHENÜBERGREIFENDES UND INTERDISZIPLINÄRES HANDBUCH MIT FALLSTUDIEN 17 (2016). 
6  MONIKA ROTH, COMPLIANCE. IN A NUTSHELL 1-9 (2015). 
7  Cf. Weber, 1922; cited after Pohlmann: MARKUS POHLMANN, SOZIOLOGIE DER ORGANISATION: EINE EIN-
FÜHRUNG 166 (2016). 
8  MARKUS POHLMANN, SOZIOLOGIE DER ORGANISATION: EINE EINFÜHRUNG 168 et seq. (2016). 
9  MARKUS POHLMANN, SOZIOLOGIE DER ORGANISATION: EINE EINFÜHRUNG 168 et seq. (2016). 	
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A. Discussing Compliance at Swiss Universities 
 
While compliance is a central topic for business enterprises, it seems to receive less atten-
tion at universities. The scientific symposium “Compliance Management at Universities 
– More than Sticking to Rules” that took place in Germany in 2012 discussed this imbal-
ance against the background of the increasingly complex regulations governing the uni-
versity landscape: rules of conduct regarding such values as scientific integrity have come 
into focus.10 Some universities have even published compliance concepts or guidelines. 
Some internal debate appears to be taking place at technical universities.11 For Switzerland, 
information on compliance is only available under the heading “scientific/scholarly integ-
rity”.12 
 
A detailed guideline explicitly called “Compliance Guide” can be found on the website of 
the Swiss Federal Institute of Technology (ETH) in Zurich.13 The ETH Zurich defines 
compliance as pursuing its goals to strengthen integrity and independent action within 
the university. The definition also includes taking measures against all situations that 
could damage the reputation of ETH Zurich. The document is intended as a binding 
guideline for all members of the university across all departments; it relates to various ar-
eas such as finance, safety, health, the environment, research involving human subjects, 
etc. Normative principles such as federal laws, university ordinances and decrees as well as 
codes of conduct regarding values and ethics are taken into account. 
 
In summary, it can be stated that there has been no discussion on compliance at universi-
ties to date, or at least no public discussion. While individual universities are dealing with 
this issue and developing tools, there seems to be no uniform concept. A striking aspect, 
though, are general statements of orientation that emerge as key themes or guidelines as 
well as codes of conduct for universities and individual departments. The importance of 
values is often addressed; however, the definition of these term often remains unclear. 
 			
10  FOM conference proceedings: Tagungsband Wissenschaftliche Fachtagung München, 22. – 23. November 
2012. Compliance-Management an Hochschulen – Mehr als Regelkonformität (2013), https://link.sprin-
ger.com/content/pdf/10.1007%2F978-3-658-01270-0_9.pdf (last visited Apr. 26, 2018, 10:48 AM) 
11  Some examples are RWTH in Aachen, Germany (cf. Nettekoven 2012), ETH in Zürich, Switzerland (ETH 
2015) or the School of Management of Law at ZHAW, also in Zürich (ZHAW 2012, 2018); ETH Compliance 
Guide (2015), https://rechtssammlung.sp.ethz.ch/Dokumente/133.pdf (last visited Apr. 26, 2018, 10:45 AM), 
ZHAW, Code of Ethics of the ZHAW School of Management and Law (2012, unpublished), and ZHAW, 
Prinzipien für eine verantwortungsvolle Managementausbildung (PRME) (2018), 
https://www.zhaw.ch/de/sml/ueber-uns/prme/ (last visited Apr. 26, 2018, 02:13 PM). 
12  See, for example, Swiss Academies of Sciences, Scientific Integrity. Compilation of codes of conduct: ZHAW, 
Dossier Wissenschaftliche Integrität (2018), https://www.zhaw.ch/de/hochschulbibliothek/schreiben-publiz-
ieren (last visited Feb. 22, 2018, 09:56 AM). 
13  ETH Zürich, Compliance Guide (2015), https://rechtssammlung.sp.ethz.ch/Dokumente/133.pdf (last visited 
Apr. 26, 2018, 01:23 PM). 	
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B. Compliance and Value Orientation 
 
In addition to the legal guidelines, compliance refers to values that are defined at a meso 
level by the organization; these are to be observed by the employees. As explained at the 
outset regarding compliance in economics, these values can be particularly relevant for 
behaviour in grey areas. If we define compliance as a behavioural concept and assume that 
employees are guided by values, the micro level also becomes relevant from the perspective 
of value research. After all, the individual value orientations of an organization’s employ-
ees shape their attitudes and can have an impact on their behaviour. According to 
Rokeach,14 values and value orientations have direct impact on behaviour; indeed, they 
are regarded as a motivational driving force for action. Value research shows that sociali-
sation, value attitudes and normative orientations all influence the decision to conform 
to or deviate from certain values. In general, value means something desirable.15 Individ-
ual reflexive values, the personal desires of individuals16 shape lives and influence goals 
and actions.17 Thus, values influence all aspects of action: the objectives, the means of 
achieving these objectives and the way in which the means are used.  It is assumed that 
external living conditions go hand in hand with internal value orientations and behav-
iours.18 
 
Careful consideration of employees’ individual reflexive value orientations within a spe-
cific university can provide information about these orientations, the specific factors in-
fluencing them and the differences or similarities existing in the different disciplines. 
 
C. ZHAW Guidelines 
 
The ZHAW is a university of applied sciences in Switzerland that comprises eight depart-
ments: Applied Linguistics; Applied Psychology, Architecture, Design and Civil Engi-
neering; Health; Life Sciences and Facility Management; School of Engineering; School 
of Management and Law; and Social Work. The employees work in teaching, research, 
development and further education, along with offering additional specialized services. 
ZHAW’s long-term goals and annual guidelines can be cited as the documents describing 
the university’s central values. The long-term value keywords are “knowledge-based and 
competence-oriented”, “transformative” and “European”. These goals were set for the 
next ten years in 2015. In addition, each year, ZHAW addresses key social challenges: for 			
14  MILTON ROCKEACH, THE NATURE OF HUMAN VALUES (1973). 
15  Clyde Kluckhohn, Value and value orientations in the theory of action, in: Toward a general theory of action 
388-433 (Talcott Parsons & Edward Shils eds., 1951). 
16  DIETER HERMANN, WERTE UND KRIMINALITÄT. KONZEPTION EINER ALLGEMEINEN KRIMINALITÄTS-
THEORIE 54 (2003). 
17  MILTON ROCKEACH, THE NATURE OF HUMAN VALUES (1973). 
18  DANIEL SEDDIG, SOZIALE WERTORIENTIERUNGEN, BINDUNGEN, NORMAKZEPTANZ UND JUGENDDE-
LINQUENZ 94 (2014). 	
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2017/2018, the focus is on energy and social integration. The focus of social integration 
can be directly related to the organization’s values. Social values are key among modern 
idealistic values, and thus it made sense for ZHAW to actively concentrate on this aspect 
in 2017/18. For instance, “Social Integration” was a conference topic at a “Retraite”19 or-
ganized by the Department of Social Work. Its aim was to develop projects that show how 
the university realizes the guiding principle of “social integration”. Following this event, 
four projects were selected and implemented with financial support. One of these pro-
moted the work integration of persons released from prison. Even more important was 
strengthening the field of social integration by means of research. In 2017, a call for pro-
posals was launched, seeking research projects focusing on work, diversity, living space 
and social security. The objective of this initiative was a long-term implementation of the 
focus. 13 projects from a wide variety of disciplines were funded.20 
 
ZHAW does not provide an explicit compliance guide, but it has drawn up several codes 
of conduct, such as the ZHAW Code of Ethics at the School of Management and LAW, 
which sets out the guiding ethical values such as respect and justice, integrity and trust-
worthiness, transparency and confidentiality, responsibility and sustainability. These ap-
ply to all activities of the ZHAW School of Management and Law, to all its employees 
and students.21 The university is also involved in the UN initiative “Principles for Respon-
sible Management Education” (PRME). PRME is an international network of over 650 
researchers and universities from 65 countries that pursues the goal of “responsible man-
agement training”, considering guiding principles of sustainability and presenting regular 
progress reports.22 However, the personal value orientations of university employees re-
main largely unknown. 
II. SAMPLE DESCRIPTION 
 
The surveys among university employees were conducted online. ZHAW has a total of 
2977 employees. The link to the online survey was sent to 1329 people; 735 of them com-
pleted the questionnaire fully or almost fully. Thus, almost 50% of the gross sample took 
			
19  In Switzerland, a “Retraite” is a form of closed meeting attended by all employees of an organizational unit. 
This event takes place outside the institution and deals with a key topic. 
20  Cf. ZHAW, Forschungsschwerpunkt Gesellschaftliche Integration, https://www.zhaw.ch/de/forschung/for-
schungsschwerpunkte/forschungsschwerpunkt-gesellschaftliche-integration/ (last visited Apr. 27, 2018, 09:36 
AM). 
21  Cf. ZHAW, Forschungsschwerpunkt Gesellschaftliche Integration, https://www.zhaw.ch/de/forschung/for-
schungsschwerpunkte/forschungsschwerpunkt-gesellschaftliche-integration/ (last visited Apr. 27, 2018, 10:25 
AM). 
22  ZHAW, Prinzipien für eine verantwortungsvolle Managementausbildung (PRME) (2018), 
https://www.zhaw.ch/de/sml/ueber-uns/prme/ (last visited Apr. 26, 2018, 11:56 AM). 	
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part in the survey, which is considered a very good result for online surveys.23 
 
In addition to structural data such as gender, age and nationality, the survey queried the 
duration of employment, the affiliation to a subject area and the religious denomination. 
To measure individual value orientation, we used an adapted form of the value scale by 
Klages extended by criminogenic values developed by Hermann24 based on two repre-
sentative questionnaires and a survey in a prison.25 In addition, in accordance with the 
prison survey, university employees were also asked questions about the judicial system 
and punitive behaviour in Switzerland. 
 
For all the following information, only those who made a statement in response to the 
respective question were included in the evaluation. 38.5 percent of the participants were 
male, and 61.5 percent female. Of the total of 6 age categories (from “under 24” to “over 
60”), the median was the age category “41 to 50”. Of the employees surveyed, around 83 
percent said they were Swiss nationals. Most of the people surveyed had a university de-
gree (around 75 percent); 35.7 percent of the respondents were administrative and/or tech-
nical personnel. 
 
A. Key value orientations of university staff members 
 
Value orientations can guide action and form behavioural strategies in private life as well 
as at work. Through an explorative factor analysis26 with the items of the questionnaire’s 
value scale, the dimensions were reduced to identify the most significant value orienta-
tions for the given sample. The procedure revealed two dimensions with a declared total 
variance of around 91 percent. According to the survey, the key values of ZHAW staff 
members are “aligning my life with religious norms and values” / “believing in God” with 
around 58 percent declared variance, and “having good friends who appreciate and accept 
you” with around 33 percent declared variance. Thus, the religious value orientation and 
the acceptance of friends form the common orientation for the sector of the employees: 
Gender and age are slightly related to these two dimensions. Women tend to ascribe cru-
cial importance to “having good friends who appreciate and accept you” more often than 			
23  Online surveys are an effective and inexpensive way of collecting and entering data. The disadvantages are also 
obvious, though: we do not know if the link reached all addressees, and what the reason for non-participation 
or abandonment of the survey were. 
24  Dieter Hermann, Individuelle reflexive Werte. Zusammenstellung sozialwissenschaftlicher Items und Skalen 
(2014), https://zis.gesis.org/skala/Hermann-Individuelle-reflexive-Werte (last visited Apr. 26, 2018, 01:31 PM). 
25  The total scale contains three main theoretical dimensions: (1) traditional values, (2) modern idealistic values 
and (3) modern materialistic values. Cf: DIETER HERMANN, WERTE UND KRIMINALITÄT. KONZEPTION 
EINER ALLGEMEINEN KRIMINALITÄTSTHEORIE (2003). 
26  Factor analysis is a method of dimension reduction. The aim is to find out which variables are central to the 
survey population. For the present study, factor analysis reduced the number of items to show more clearly 
what ZHAW employees understand by values. Main component analysis with Varimax rotation was selected 
for this purpose. Transverse charges were extracted if not uniquely loaded on a factor. The factor analysis pro-
cedure was carried out until a clear structure with the highest possible explanatory power emerged. 	
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men (.149)27, and older respondents tend to focus on “religious norms and values” more 
often than younger respondents (.130).  
 
B. Age and gender 
 
As noted previously, there is a weak link between gender and value orientation, which is 
in line with the general tendencies known from value research;28 however, clear-cut diver-
gences between age groups cannot be identified from the age categories available to us: 
the influence is rather weak. The median age category is “41 to 50”. The central value ori-
entations following from the factor analysis suggest that religion and friends matter to 
almost all respondents, thus forming their common denominator. In the following, we 
will show the variables influenced by the gender of the respondents.  
 
  
 
Figure 1. 			
27  The correlation coefficient is a measure of the degree of linear correlation between two at least interval-scaled 
characteristics. It can have values between - 1 and +1. If the value is 0, there is no connection. 
28  DIETER HERMANN, WERTE UND KRIMINALITÄT. KONZEPTION EINER ALLGEMEINEN KRIMINALITÄTS-
THEORIE (2003). 
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The figure only shows the significant differences in value orientations differentiated by 
gender. According to these data, security, inner peace and health matter more to women 
than to men. Women are more emotionally driven than men, and friends are even more 
important to them than to the male respondents. It is important for women to enjoy life 
and to help socially disadvantaged people. The final variable was not highly significant 
but is included in the analysis because it suggests that women tended to be more differen-
tiated in their responses, considering the value of individual items closely rather than 
simply ticking the category “very important”. “Hard and tough” is one of the crimino-
genic values from the Hermann 2003 value scale; it tends to be preferred by men rather 
than women29. Analysing the influence of sociodemographic factors in the value orienta-
tion in youth, Pöge also concluded that gender influences value orientation.30 Since social 
integration is particularly important for the institution, the variable “helping socially dis-
advantaged groups” is exemplarily examined in more detail. By means of a regression anal-
ysis,31 the variability of response to “helping socially disadvantaged groups” is explained 
mainly by gender, followed by age and finally by profession. Comparisons of the mean 
values do not give a clear picture here: members of the departments of Social Work, 
Health and Psychology and Linguistics rate the variable “helping socially disadvantaged 
groups” the highest, followed by members of the departments of Management and Law, 
as well as Engineering – but the differences are not always statistically significant. It is 
remarkable that the initiatives in the framework of the social integration guideline not 
only come from professions that traditionally have a close connection to social engage-
ment – rather, the topic has met with great interest in all areas. 
III. SUMMARY 
 
In the educational field, the discussion of compliance is still in its infancy. Still, the guide-
lines and stated priorities of institutions merit attention: these often are de facto compli-
ance statements in the broadest sense. ZHAW is an example of an institution whose pri-
orities are not only well-considered but also actively implemented. The priority area “So-
cial Integration”, for instance, receives credibility and sustainability from the connection 
to research priorities, including the promotion of practical projects. A look at the em-
ployee level also shows considerable interest in social integration. Traditionally, such a 
focus is considered easier to implement in professions committed to the social realm than 
in the technical and other professions – however, our study shows that characteristics 
such as gender and age offer more explanatory power than professional self-identification. 
			
29  Melanie Wegel/Anna Isenhardt/Maria Kamenowski, Geschlecht und Delinquenz: Die Wertetheorie und ihr 
Erklärungspotenzialmit Blick auf weibliche Inhaftierte, 30 (2) NEUE KRIMINALPOLITIK, 189 – 209 (2018). 
30  ANDREAS PÖGE, WERTE IM JUGENDALTER (2017). 
31  The model was significant overall: Durbin Watson 1.92. 
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ABSTRACT 
This article discusses the potential role of incentive systems in combating bribery. In partic-
ular, it uses an agency theory approach to show how a combination of bonus and malus 
payments could help to eliminate bribery in multinational corporations. Expert interviews 
with 35 anti-bribery specialists from Austria, Germany, Liechtenstein, and Switzerland 
were conducted and analyzed through qualitative content analysis. It was found that em-
ployees should be rewarded for both productivity and compliance. In addition, performance 
should be measured in a matrix and whistleblowers should receive a bonus for reporting 
undesired behavior. Conversely, significant risks associated with incentives for whistleblow-
ing were also identified. Whilst the empirical findings focus on Europe, their implications 
could be applied globally. 
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I. INTRODUCTION 
 
Twenty years ago, bribery was still commonly accepted in many areas of the world. How-
ever, corruption leads to inefficient use of resources, unfair redistribution of income, and 
secessionist responses.1 Frustration, unstable sociopolitical situations, and a lack of con-
tentment among private citizens are just a few of the potential outcomes.2 In addition, 
bribery requires secrecy, which makes the enforcement of agreements very difficult.3 
Given its many negative impacts on a country’s development, multiple nations have out-
lawed bribery.4 
 
However, bribery has not yet been eliminated, with multiple attempts to combat this 
phenomenon ultimately failing. This article will present an agency theory-based approach 
towards eliminating bribery. In particular, it will analyze and discuss whether incentive 
systems could be adjusted to more effectively fight bribery in multinational corporations, 
thereby helping to decrease corruption in developing countries. 
II. LITERATURE REVIEW 
 
For this study’s purpose, the bribery definitions of the OECD Anti-Bribery Convention 
and Transparency International are amalgamated to define bribery as an act in which a 
party:  
intentionally abuses entrusted power for private gain by offering, promising, or giving 
any undue pecuniary or other advantage, whether directly or through intermediaries, 			
1  Mark Levin & Georgy Satarov, Corruption and institutions in Russia, EUROPEAN JOURNAL OF POLITICAL 
ECONOMY, 16(1), 113, 114f. (2000); Antonio Argandoña, The United Nations convention against corruption and 
its impact on international companies, JOURNAL OF BUSINESS ETHICS, 74(4), 481, 482 (2007); Michael W. 
Collier, Explaining corruption: An institutional choice approach, CRIME, LAW AND SOCIAL CHANGE, 38(1), 1, 
6(2002). 
2  Christopher J. Anderson & Yuliya V. Tverdova., Corruption, political allegiances, and attitudes toward govern-
ment in contemporary democracies, AMERICAN JOURNAL OF POLITICAL SCIENCE, 47(1), 91 , 104 (2003); Pak 
Hung Mo, Corruption and economic growth, JOURNAL OF COMPARATIVE ECONOMICS, 29(1), 66, 67 (2001); 
Jong Bum Kim, Korean implementation of the OECD bribery convention: Implications for global efforts to fight 
corruption, UCLA PACIFIC BASIN LAW JOURNAL, 17(2/3), 245, 249 (1999). 
3  Paolo Mauro, Why worry about corruption?, ECONOMIC ISSUES 6. WASHINGTON, D.C.: INTERNATIONAL 
MONETARY FUND, 6 (1997); Pranab Bardhan, Corruption and development: A review of issues. JOURNAL 
OF ECONOMIC LITERATURE, 35(3), 1320, 1320 (1997); Paolo Mauro, The effects of corruption on growth, 
investment, and government expenditure, IMF WORKING PAPER, WP/96/98 WASHINGTON, D.C.: INTERNA-
TIONAL MONETARY FUND, 86 (1996); John Bray, The use of intermediaries and other alternatives to bribery, 
in: The new institutional economics of corruption, 120(Johann Graf Lambsdorff, Markus Taube & Matthias 
Schramm eds., 2005). 
4  Hongyi Li, Lixin Colin Xu & Heng-fu Zou, Corruption, income distribution, and growth, ECONOMICS & 
POLITICS, 12(2), 155, 156 (2000); Aart Kraay, Pablo Zoido-Lobaton & Daniel Kaufmann, Aggregating govern-
ance indicators, POLICY RESEARCH WORKING PAPER 2195 WASHINGTON, D.C.: WORLD BANK, 3 (1999). 	
		 COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
FABIAN M. TEICHMANN    |  		ELIMINATING BRIBERY - AN INCENTIVE-BASED APPROACH 
 
PAGE  75 
to a foreign public official, for that official or for a third party, in order that the 
official act or refrain from acting in relation to the performance of official duties, in 
order to obtain or retain business or other improper advantage in the conduct of in-
ternational business.5 
This definition is ideal for this study since countries throughout the world have based 
their national legislation on the OECD Anti-Bribery Convention. Moreover, Transpar-
ency International’s definition is the approach employed in the best-known corruption 
index.  
 
This study employs an agency theory approach. In particular, it will emphasize that “prin-
cipals” and “agents” have differing interests6, and that the former commonly desire to be 
compensated for acting in accordance with the latter’s best interests.7 Ultimately, princi-
pals bear responsibility for the outcome of a task delegated to their agents.8 This is partic-
ularly problematic if agents are unsupervised9, in which circumstance they might shirk or 
use the corporation’s resources for their own benefit.10 This constitutes a significant chal-
lenge as regards bribery, which is commonly conducted secretly, such that shareholders 
and CEOs (principals) may not always be aware of actions taken by the company’s sales 
managers (agents). In this context, incentives could potentially prevent employees from 
simply reducing their risk and forcing the owners to bear a bigger share of it.11 Of course, 
internal audits and control mechanisms could be used simultaneously to address agency 
problems.12 
 
 
However, the use of incentives to fight bribery has not yet been investigated in depth. 			
5  See FAQs on corruption, December 20, 2015, TRANSPARENCY INTERNATIONAL, http://www.transpar-
ency.org/whoweare/organisation/faqs_on_corruption (last visited 10 Oct. 2018), 1 (2015); OECD, Convention 
on Combating Bribery of Foreign Public Officials in International Business Transactions and related documents, 
6(4), OECD WORKING PAPERS, https://www.oecd.org/daf/anti-bribery/ConvCombatBribery_ENG.pdf 
(last visited 10 Oct. 2018), 7 (2011). 
6  Kathleen M. Eisenhardt, Agency theory: An assessment and review, ACADEMY OF MANAGEMENT REVIEW, 
14(1), 57, 59 (1989). 
7  Patrick McColgan, Agency theory and corporate governance: A review of the literature from a UK perspective, 
6 (2001). 
8  Stephen A. Ross, The economic theory of agency: The principal’s problem, THE AMERICAN ECONOMIC RE-
VIEW, 63(2), 134, 134 (1973) 
9  Peter Wright, Ananda Mukherji & Mark J.Kroll, A reexamination of agency theory assumptions: Extensions 
and extrapolations, THE JOURNAL OF SOCIO-ECONOMICS,30(5), 413, 426 (2001). 
10  Luis R. Gomez-Mejia & David B. Balkin, Determinants of faculty pay: An agency theory perspective, ACADEMY 
OF MANAGEMENT JOURNAL, 35(5), 921, 923 (1992). 
11  Henry L. Tosi, Jr. & Luis R. Gomez-Mejia, The decoupling of CEO pay and performance: An agency theory 
perspective, ADMINISTRATIVE SCIENCE QUARTERLY, 34(2), 169, 169 (1989). 
12  Michael B. Adams, Agency theory and the internal audit, MANAGERIAL AUDITING JOURNAL, 9(8), 8, 12 
(1994). 	
		 COMPLIANCE  ELLIANCE  JOURNAL   |    VOLUME 4   NUMBER 2   2018 
FABIAN M. TEICHMANN    |  		ELIMINATING BRIBERY - AN INCENTIVE-BASED APPROACH 
 
PAGE  76 
The overwhelming majority of literature on wages and bribery has focused on the public 
sector and on adequate wages in general, rather than on incentives.13 For instance, it has 
been analyzed whether tax collectors openness to bribery may be increased by using in-
centive systems.14 It has also been discussed whether graders in Burkina Faso are more or 
less likely to accept bribes under bonus or malus systems.15 In contrast to previous studies, 
this article will analyze whether incentive systems could help to eliminate bribery in mul-
tinational corporations. 
III. METHODY 
 
Due to the significant research gap identified above, it was not possible to form hypothe-
ses that could be quantitatively tested. Therefore, an explorative approach was chosen.16 
Thirty-five formal interviews were conducted with anti-bribery experts from Austria, 
Germany, Liechtenstein, and Switzerland, aiming to answer the following research ques-
tions: 
 
How could incentive systems help to prevent corruption in multinational corpora-
tions? 
 
Which risks are associated with anti-bribery incentives? 
 
The interviewees were recruited through the author’s personal network, and the inter-
views were transcribed and analyzed using qualitative content analysis.17 The recruited in-
terviewees have various backgrounds. First, 15 white-collar criminals were interviewed in 
			
13  Rajeev K. Goel & Daniel P. Rich, On the economic incentives for taking bribes, PUBLIC CHOICE, 61(3),269, 
269f. (1989); Rafael Di Tella & Ernesto Schargrodsky, (2003). The role of wages and auditing during a crack-
down on corruption in the city of Buenos Aires, JOURNAL OF LAW AND ECONOMICS, 46(1), 269, 269f. (2003); 
Gary S. Becker & George J. Stigler, Law enforcement, malfeasance, and compensation of enforcers, THE JOUR-
NAL OF LEGAL STUDIES, 3(1), 1, 6 (1974); Caroline Van Rijckeghem & Beatrice Weder, Bureaucratic corruption 
and the rate of temptation: Do wages in the civil service affect corruption, and by how much?, JOURNAL OF 
DEVELOPMENT ECONOMICS, 65(2), 307, 307 (2001). 
14  Timothy Besley & John McLaren, Taxes and bribery: The role of wage incentives, THE ECONOMIC JOURNAL, 
103(416), 119, 137 (1993); Dilip Mookherjee, Incentive reforms in developing country bureaucracies: Lessons from 
tax administration, in: Annual World Bank Conference On Development Economics, 103 (Boris Pleskovic & 
Joseph. E. Stiglitz eds., 1997). 
15  Olivier Armantier & Amadou Boly, On the effects of incentive framing on bribery: Evidence from an experi-
ment in Burkina Faso, ECONOMICS OF GOVERNANCE, 15(1), 1, 13 (2014). 
16  Robert M. Bowen, Andrew C. Call & Shiva Rajgopal, Whistle-blowing: Target firm characteristics and eco-
nomic consequences, THE ACCOUNTING REVIEW, 85(4), 1239–1271 (2010); Kevin Buckler, The quantita-
tive/qualitative divide revisited: A study of published research, doctoral program curricula, and journal editor 
perceptions, JOURNAL OF CRIMINAL JUSTICE EDUCATION, 19(3), 383–403 (2008); JOHN W. CRESWELL,  RE-
SEARCH DESIGN: QUALITATIVE, QUANTITATIVE, AND MIXED METHOD APPROACHES 183 (4th ed., 2013). 
17  PHILIPP MAYRING, QUALITATIVE INHALTSANALYSE: GRUNDLAGEN UND TECHNIKEN, 10f (11th ed., 2010). 	
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order to understand the perspective of those committing bribery. Subsequently, 20 pre-
vention and law enforcement experts were interviewed. Eight interviewees were recruited 
from big four consulting firms prominent in the field of anti-bribery compliance in mul-
tinational corporations. This allowed particular focus on fraud investigation and dispute 
services. Eight compliance officers of multinational corporations, responsible for design-
ing and implementing anti-bribery policies, were also interviewed. Finally, four law en-
forcement experts were interviewed. In analyzing the interviews, a category system was 
formed and assessed on its objectivity, reliability, and validity through triangulation. 18 
IV. EMPIRICAL RESULTS 
 
According to the partners of the big four consulting firms, both productivity and com-
pliance should be remunerated, since employees are expected to be productive and act 
compliantly. By only paying them for productivity, employees may seek non-compliant 
ways of increasing their output. In this context, current incentive systems may even en-
courage employees to break compliance rules.  
 
However, the compliance officers in multinational corporations contended that reward-
ing both productivity and compliance can be rather challenging, given the difficulty of 
determining whether an employee has acted compliantly or not. Therefore, it is im-
portant to use performance matrixes that include several types of output.  
 
The partners of the big four consulting firms also suggested introducing a bonus and ma-
lus system, as well as a bonus bank. Employees could then be rewarded for productivity 
and compliance, with small compliance violations (those that are not grounds for termi-
nating employment) resulting in a malus deduction from their bonus bank. This could 
help to partially overcome the lack of transparency commonly associated with bribery, 
since acts of non-compliance may be discovered several years after their commission. Bo-
nus banks could, thus, help to ensure that employees paying bribes are not rewarded eco-
nomically for their actions.  
 
The white-collar criminals suggested rewarding whistleblowing as an additional control 
mechanism. The underlying reasoning is that employees (agents) can control one another 
but need an incentive to be willing to report their peers. Hence, a bonus could be paid for 
whistleblowing. 
 
Conversely, the compliance officers emphasized that bonus payments for whistleblowing 
could lead to false accusations and, hence, unnecessary investigations. In addition, such 			
18  Marilyn Healy & Chad Perry, Comprehensive criteria to judge validity and reliability of qualitative research 
within the realism paradigm, QUALITATIVE MARKET RESEARCH, 3(3), 118, 118f (2000).; Nicholas Mays & 
Catherine Pope, Assessing quality in qualitative research, BRITISH MEDICAL JOURNAL, 320(7226), 50, 50 
(2000); Janice M. Morse, Michael Barrett, Maria Mayan, Karin Olson & Jude Spiers, Verification strategies for 
establishing reliability and validity in qualitative research, INTERNATIONAL JOURNAL OF QUALITATIVE 
METHODS, 1(2), 13, 13f (2002). 
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whistleblowing bonuses could have a negative impact in team-based cultures, since people 
could stop trusting one another. 
V. CONCLUSION 
 
Incentive systems could play an important role in eliminating bribery. In particular, em-
ployees should be rewarded for both productivity and compliance, with performance 
measured through matrixes. In addition, a combination of bonus and malus payments 
could help to reward compliant and sanction non-compliant behavior. Bonus payments 
for whistleblowing could also help to establish an additional control mechanism. In this 
context, however, it should be kept in mind that whistleblowing bonuses could lead to 
false accusations and destroy the team-based cultures central to many corporations. Fi-
nally, it should be recognized that a study with a larger sample conducted in different 
countries or at a different time could produce different results.19 
			
19  Janice M. Morse, Michael Barrett, Maria Mayan, Karin Olson & Jude Spiers, Verification strategies for estab-
lishing reliability and validity in qualitative research, INTERNATIONAL JOURNAL OF QUALITATIVE METH-
ODS, 1(2), 13, 18 (2002); FABIAN M. TEICHMANN, ANTI-BRIBERY COMPLIANCE INCENTIVES, 10f (2017). 
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A few weeks ago, I was finally able to hold in my hands the book of my colleague, friend, 
and co-founder of the CEJ, Michele DeStefano. I read it almost from top to bottom in 
one go, with great pleasure and with the highest appreciation. 
 
At a meeting in Berlin, Michele, still in the middle of her creative process, explained to me 
that her book was about the "innovation tournament"1 in the legal consulting market. The 
result, if one wants to assign it to the established genres of legal literature, cannot fit into 
any category. The empirical core of the paper consists of over 100 quality interviews from 
"GCs and chief executives from large international organizations along with heads of in-
novations and law firm partners from around the world"2.In terms of methodology, 
DeStefano builds on her previous papers3 and inductively develops statements regarding 
the self-perception and external perception of cooperation between law firms and their 
clients from industry and business. The result of such analyses is an innovative paper in 
the area of law and sociology regarding the legal professions and the demands placed on 
them by their corporate clients. However, the paper also gives specific recommendations 
regarding change management in the legal marketplace4 in the form of a "cookbook" and 
regarding the adaptation of products and the billing (pricing) of services provided by law 
firms to the changing needs of effective legal consulting.  
 
DeStefano succeeds in combining scientific substance and practical relevance and present-
ing her findings in an exciting, intuitive narrative style. The paper breaks new ground 
with the question that is pursued and with the scientific approach, as the analysis regard-
ing the compatibility of the services provided by law firms with the needs of their clients 
is grounded empirically for the first time, and the paper makes visible and documents the 
connections that were previously surmised and felt, but not scientifically structured and 
documented, by the actors on the legal market. 
 
The theoretical frame of reference of the paper consists of a reconstruction of the social, 
legal, and economic environment of the legal market.5 Changes to this environment create 
a situation of pressure for law firms, rendering inevitable an adaptation and reorientation 
			
1  p. 20 et seq, page references here and below refer to MICHELE DESTEFANO, LEGAL UPHEAVAL: A GUIDE TO 
CREATIVITY, COLLABORATION, AND INNOVATION IN LAW (2018). 
2  p. 217. 
3  Michele DeStefano, Creating A Culture Of Compliance: Why Departmentalization May Not Be The Answer, 
10 (1) HASTINGS BUSINESS LAWJOURNAL, 71 et seq. (2014). 
4  p. 157 et seq. 
5  p. 3 et seq. 	
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of legal advisory services, along with a redefinition of the relationship between the corpo-
rate client and the external law firm ("innovate or die"6). DeStefano identifies three factors 
of influence or forces that generate such pressure to innovate. Technology (for example, 
artificial intelligence, blockchain) means that certain standardizable services (drafting of a 
contract, prediction of the chances of success of proceedings, etc.) no longer have to be 
developed or worked out by attorneys "by hand"; rather, such technology may be available 
on demand within the framework of digital solutions. This changes the price structure of 
the products and the manner in which they are commissioned and called up. DeStefano 
illustrates this with the examples of copyright registrations and trademark filings7, which 
can be undertaken today more cost-effectively and more rapidly without an attorney 
through the services of specialized providers of technical solutions. This translates into a 
change in demand for traditional consulting and requires a differentiation between ser-
vices that can be provided with the assistance of technology or solely through technology, 
and those that require personal legal consulting and problem solving. As the second driver 
of change, the author refers to socio-economic and demographic changes, which will not 
stop with the future clients of law firms. Digital natives will confront advisory law firms 
with requirements regarding communication, teamwork, technology, etc. that are differ-
ent than those of the "workforce traditionalists" or "baby boomers" generations (p. 7). The 
third factor of influence is the evolution of legal material, which can be observed around 
the world and is of increasing importance, as legal issues often have references both to 
local law and to the law of other nations and legal cultures. The pitfalls that can occur in 
international internal investigations provide an example of this,8 because a variety of is-
sues in areas of labor law, criminal law and data protection must be identified and man-
aged ("globality and glocality"9).  
 
The responses of GCs, to which DeStefano refers in her section entitled "the lawyer skills 
delta," indicate that the needs of GCs in the companies seeking legal assistance are often 
not adequately met by the commissioned attorneys. The requirement profile consists of 
an "end-to-end solution." An interviewee10 describes this as "the optimal combination of 
people, process, tools and technology, and hybrid inside / outside sourcing models, to 
meet their client’s business and legal challenges." Accordingly, profound legal expertise is 
merely a basic requirement to meet the requirements of clients. For this reason, the nar-
rower sense, DeStefano does not even count such technical qualifications among the three 
levels, from the basis of satisfactory performance up to best practice with an "ecstatic cli-
ent." In a legal environment that DeStefano rightly describes, in the style of Cold War 
			
6  p. 133. 
7  p. 12. 
8  Hendrik Schneider, The Enterprise in Testudo Formation, 3(1) CEJ, 43 (2017); p. 50 et seq. 
9  p. 8 et seq. 
10  p. 34. 	
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military terminology, as "VUCA" (volatile, uncertain, complex and ambiguous11), the ex-
ternal legal adviser should offer solutions and directions, and not simply point out prob-
lems. Anyone who is already drowning in e-mails12 does not need a paper mountain or 
"over the top legal advice"13; rather, such person needs a strategic partner with empathy 
and the right answers for the task to be accomplished together. 
 
However, it must also be mentioned that this also depends on the specific task with regard 
to the depth of content and the scope of the consulting service. A "hedged report" that 
legally assesses a particular transaction and is intended to serve as argumentative substan-
tiation in (future) criminal or civil proceedings follows premises different than legal ad-
vice within the framework of an in-house process, such as advising an e-health start-up, 
which collects data in compliance with the law and wants to bring to market innovative 
medical devices for smart diagnostics around the world.  
 
Furthermore, the qualitative interviews make it very understandable that the differentia-
tion of the legal material often compels cooperation in a team of multiple specialists. This 
distinguishes GCs from their external consultants. While the former are often legal gen-
eralists, who have broad basic knowledge in various legal matters, external expertise is ac-
quired on special issues. In an interview with a law firm based in New York, one partner 
says "I know a whole lot of a tiny area of law"14. This depth of knowledge is required to 
provide the desired legal information quickly, confidently and accurately. However, con-
structive cooperation with other experts within and outside the consulting firm is re-
quired to successfully manage the entire project. As such, in the innovation tournament, 
only a person who has expertise in "collaborative creative problem finding and solving" 
can assert himself or herself15. 
 
The author is aware that it is not only the case that such expertise is often neither reflected 
nor promoted in the workplace; it is also neglected in traditional legal education. With 
the worldwide university program LawWithoutWalls,16 as she brings it to life, she has suc-
ceeded in closing this gap, occupying the interface between law, business and technology, 
and supporting students in building up the key interdisciplinary qualifications necessary 
to support the drive to innovate ("building collaborative relationships"). DeStefano suc-
cessfully applies the know-how gained in this process in the design of the innovation pro-
cess ("regardless of the size or location of your firm or legal department"17). 			
11  p. 10. 
12  p. 39. 
13  p. 50. 
14  p. 10. 
15  p. 49.  
16  see Appendix B, p. 214 et seq. 
17  p. VI. 	
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The entire paper is so motivating and full of inspiration and new ideas that it is immedi-
ately contagious. The reader will want to put into effect what Michele DeStefano de-
scribes and teaches, both at the university and in the practice of legal consulting. Congrats, 
Michele, particularly for the many quotes and examples that will stay in my mind and 
surely the minds of other readers - from the "Man in the Mirror"18 to "Mr. Wolf" in "Pulp 
Fiction"19. 
			
18  p. 56. 
19  p. 64. 
